Home The Word Brain	My Amedeo FAQ Privacy About
	2049 Chinese The 20K Word Road to Mandarin Proficiency By B. S. Kamps et al.

Chronic Heart Failure

Free Subscription Articles published in Eur Heart J Retrieve available abstracts of 422 articles: HTML format

Single Articles

May 2024
1. DUBIN RF, Deo R, Ren Y, Wang J, et al
   Incident heart failure in chronic kidney disease: proteomics informs biology and risk stratification.
   Eur Heart J. 2024 May 17:ehae288. doi: 10.1093.
   PubMed     Abstract available
   
   
   
2. SHAH SJ, Sharma K, Borlaug BA, Butler J, et al
   Semaglutide and Diuretic Use in Obesity-Related Heart Failure with Preserved Ejection Fraction: A Pooled Analysis of the STEP-HFpEF and STEP-HFpEF-DM trials.
   Eur Heart J. 2024 May 13:ehae322. doi: 10.1093.
   PubMed     Abstract available
   
   
   
3. PACKER M, Anker SD, Butler J, Cleland JGF, et al
   Identification of three mechanistic pathways for iron-deficient heart failure.
   Eur Heart J. 2024 May 11:ehae284. doi: 10.1093.
   PubMed     Abstract available
   
   
   
4. CLEPHAS PRD, Zwartkruis VW, Malgie J, van Gent MWF, et al
   Pulmonary artery pressure monitoring in chronic heart failure: effects across clinically relevant subgroups in the MONITOR-HF trial.
   Eur Heart J. 2024 May 11:ehae323. doi: 10.1093.
   PubMed     Abstract available
   
   
   
5. WANG R, Schiattarella GG
   Tackling metabolic defects in HFpEF.
   Eur Heart J. 2024;45:1494-1496.
   PubMed    
   
   
   April 2024
6. JACKSON AM, Goland S, Farhan HA, Yaseen IF, et al
   A novel score to predict left ventricular recovery in peripartum cardiomyopathy derived from the ESC EORP Peripartum Cardiomyopathy Registry.
   Eur Heart J. 2024;45:1430-1439.
   PubMed     Abstract available
   
   
   
7. CREA F
   The complex interaction between cancer, ischaemic heart disease, and heart failure, and a focus on arrhythmias including risk stratification in Brugada syndrome and leadless pacing.
   Eur Heart J. 2024;45:1183-1187.
   PubMed    
   
   
   
8. RUZIEH M
   Comparative effectiveness research using claims data: meticulous methods don't solve old problems.
   Eur Heart J. 2024;45:1284.
   PubMed    
   
   
   
9. WU VC, Yeh JK, Chen SW, Wu CL, et al
   Syphilis and cardiovascular risk: a Taiwanese registry.
   Eur Heart J. 2024 Apr 3:ehae183. doi: 10.1093.
   PubMed     Abstract available
   
   
   March 2024
10. ALCOCER-GAMBA MA, Alvarez-Sangabriel A, de la Parra-Calderon JA
    Management of heart failure in Mexico: challenges and opportunities.
    Eur Heart J. 2024 Mar 29:ehae059. doi: 10.1093.
    PubMed    
    
    
    
11. PEDICINO D, Volpe M
    Weekly journal scan: a hard RAFTing to improve long-term survival in heart failure with severely reduced ejection fraction.
    Eur Heart J. 2024 Mar 28:ehae167. doi: 10.1093.
    PubMed    
    
    
    
12. WYLD M, Webster AC
    Myocardial infarction and stroke in patients with kidney failure: can we do better?
    Eur Heart J. 2024 Mar 27:ehae153. doi: 10.1093.
    PubMed    
    
    
    
13. SCHUERMANS A, Vlasschaert C, Nauffal V, Cho SMJ, et al
    Clonal haematopoiesis of indeterminate potential predicts incident cardiac arrhythmias.
    Eur Heart J. 2024;45:791-805.
    PubMed     Abstract available
    
    
    
14. CLELAND JGF, Kalra PA, Pellicori P, Graham FJ, et al
    Intravenous iron for heart failure, iron deficiency definitions, and clinical response: the IRONMAN trial.
    Eur Heart J. 2024 Mar 6:ehae086. doi: 10.1093.
    PubMed     Abstract available
    
    
    
15. CHAIX MA, Dore A, Mondesert B, Mongeon FP, et al
    Angiotensin receptor-neprilysin inhibitor vs. placebo in congenital systemic right ventricular heart failure: the PARACYS-RV trial.
    Eur Heart J. 2024 Mar 6:ehad890. doi: 10.1093.
    PubMed    
    
    
    
16. SAYOUR NV, Paal AM, Ameri P, Meijers WC, et al
    Heart failure pharmacotherapy and cancer: pathways and pre-clinical/clinical evidence.
    Eur Heart J. 2024 Mar 5:ehae105. doi: 10.1093.
    PubMed     Abstract available
    
    
    
17. MURARU D, Badano LP, Hahn RT, Lang RM, et al
    Atrial secondary tricuspid regurgitation: pathophysiology, definition, diagnosis, and treatment.
    Eur Heart J. 2024 Mar 5:ehae088. doi: 10.1093.
    PubMed     Abstract available
    
    
    
18. 
    Correction to: Conventional heart failure therapy in cardiac ATTR amyloidosis.
    Eur Heart J. 2024 Mar 1:ehae140. doi: 10.1093.
    PubMed    
    
    
    February 2024
19. ZURKAN D, Pitt B, Edelmann F
    Mineralocorticoid receptor antagonists for the prevention of atrial fibrillation in patients with and without heart failure: one more beneficial effect?
    Eur Heart J. 2024 Feb 6:ehae040. doi: 10.1093.
    PubMed    
    
    
    January 2024
20. BERNARDO MC, Carvalho SS, Moreira I
    Massive myocardial calcification as an aetiology of heart failure.
    Eur Heart J. 2024 Jan 23:ehae009. doi: 10.1093.
    PubMed    
    
    
    
21. BAUERSACHS J, de Boer RA, Zieroth S
    The year in cardiovascular medicine 2023: the top 10 papers in heart failure and cardiomyopathies.
    Eur Heart J. 2024 Jan 18:ehad878. doi: 10.1093.
    PubMed    
    
    
    
22. GALIUTO L, Volpe M
    A new RNA-interference based strategy is associated with mild beneficial effects in patients with heart failure due to cardiac amyloidosis.
    Eur Heart J. 2024 Jan 18:ehae015. doi: 10.1093.
    PubMed    
    
    
    
23. DOEHNER W, Akyea RK, Ntaios G
    The obesity paradigm on outcome in heart failure with reduced ejection fraction.
    Eur Heart J. 2024 Jan 18:ehad761. doi: 10.1093.
    PubMed    
    
    
    
24. BUTT JH, McMurray JJV
    The obesity paradigm on outcome in heart failure with reduced ejection fraction.
    Eur Heart J. 2024 Jan 18:ehad764. doi: 10.1093.
    PubMed    
    
    
    
25. AHN HJ, An HY, Ryu G, Lim J, et al
    Clonal haematopoiesis of indeterminate potential and atrial fibrillation: an east Asian cohort study.
    Eur Heart J. 2024 Jan 17:ehad869. doi: 10.1093.
    PubMed     Abstract available
    
    
    
26. PELLICORI P, Hunter D, Ei Khin HH, Cleland JGF, et al
    How to diagnose and treat venous congestion in heart failure.
    Eur Heart J. 2024 Jan 9:ehad883. doi: 10.1093.
    PubMed    
    
    
    
27. ORAII A, Healey JS, Kowalik K, Pandey AK, et al
    Mineralocorticoid receptor antagonists and atrial fibrillation: a meta-analysis of clinical trials.
    Eur Heart J. 2024 Jan 9:ehad811. doi: 10.1093.
    PubMed     Abstract available
    
    
    
28. KAMBIC T, Lavie CJ, Eijsvogels TMH
    Seeking synergy for novel weight- and glucose-lowering pharmacotherapy and exercise training in heart failure patients with preserved ejection fraction.
    Eur Heart J. 2024 Jan 8:ehad856. doi: 10.1093.
    PubMed    
    
    
    December 2023
29. 
    Correction to: Participation in a clinical trial is associated with lower mortality but not lower risk of HF hospitalization in patients with heart failure: observations from the ESC EORP Heart Failure Long-Term Registry.
    Eur Heart J. 2023 Dec 21:ehad855. doi: 10.1093.
    PubMed    
    
    
    
30. ABU-OWN H, Webb I, Okonko DO
    Intravenous iron repletion in heart failure: bridging the gap between symptom relief and hard clinical outcomes.
    Eur Heart J. 2023;44:5092-5094.
    PubMed    
    
    
    
31. KRAMARENKO D, Walsh R
    Emery-Dreifuss muscular dystrophy: a closer look at cardiac complications.
    Eur Heart J. 2023;44:5074-5076.
    PubMed    
    
    
    
32. LI XM, Zhu XJ, Jing ZC
    Reverse cardiac remodelling after balloon atrial septostomy for pulmonary arterial hypertension and end-stage heart failure.
    Eur Heart J. 2023 Dec 16:ehad822. doi: 10.1093.
    PubMed    
    
    
    
33. MULLER FS, Aherrahrou Z, Grasshoff H, Heidorn MW, et al
    Autoantibodies against the chemokine receptor 3 predict cardiovascular risk.
    Eur Heart J. 2023;44:4935-4949.
    PubMed     Abstract available
    
    
    
34. MEHRA MR, Castagna F, Butler J
    The transformative potential of left ventricular assist devices in advanced heart failure: no more a therapeutic orphan.
    Eur Heart J. 2023 Dec 11:ehad555. doi: 10.1093.
    PubMed    
    
    
    
35. KHAN MS, Usman MS, Van Spall HGC, Greene SJ, et al
    Endpoint adjudication in cardiovascular clinical trials.
    Eur Heart J. 2023;44:4835-4846.
    PubMed     Abstract available
    
    
    
36. WESTWOOD M, Almeida AG, Barbato E, Delgado V, et al
    Competency-based cardiac imaging for patient-centred care. A statement of the European Society of Cardiology (ESC). With the contribution of the European Association of Cardiovascular Imaging (EACVI), and the support of the Association of Cardiovascul
    Eur Heart J. 2023;44:4771-4780.
    PubMed     Abstract available
    
    
    November 2023
37. SCHMITTO JD, Shaw S, Garbade J, Gustafsson F, et al
    Fully magnetically centrifugal left ventricular assist device and long-term outcomes: the ELEVATE registry.
    Eur Heart J. 2023 Nov 30:ehad658. doi: 10.1093.
    PubMed     Abstract available
    
    
    
38. 
    Correction to: 2023 Focused Update of the 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: Developed by the task force for the diagnosis and treatment of acute and chronic heart failure of the European Society of
    Eur Heart J. 2023 Nov 23:ehad613. doi: 10.1093.
    PubMed    
    
    
    
39. CREA F
    Fighting the pandemic of heart failure: better utilization of current treatments, new drugs, and new therapeutic targets.
    Eur Heart J. 2023;44:4607-4611.
    PubMed    
    
    
    
40. TOMII D, Praz F, Windecker S
    Guideline directed medical therapy in patients with heart failure undergoing transcatheter edge-to-edge mitral valve repair: unfulfilled premise.
    Eur Heart J. 2023 Nov 15:ehad678. doi: 10.1093.
    PubMed    
    
    
    
41. HENRY CM, Oseran AS, Zheng Z, Dong H, et al
    Cardiovascular Hospitalizations and Mortality Among Adults Aged 25 to 64 years in the United States.
    Eur Heart J. 2023 Nov 11:ehad772. doi: 10.1093.
    PubMed     Abstract available
    
    
    
42. JESSEN N, Mocumbi AO, Sliwa K
    Heart failure in Africa: challenges of dealing with a heterogeneous syndrome in a heterogeneous continent.
    Eur Heart J. 2023 Nov 9:ehad742. doi: 10.1093.
    PubMed    
    
    
    
43. WERT L, Falk V, Potapov EV
    Severe aortic regurgitation after short-term treatment with microaxial left ventricular assist device in the transaxillary approach.
    Eur Heart J. 2023 Nov 9:ehad750. doi: 10.1093.
    PubMed    
    
    
    
44. KIYUNA LA, Candido DS, Bechara LRG, Jesus ICG, et al
    4-Hydroxynonenal impairs miRNA maturation in heart failure via Dicer post-translational modification.
    Eur Heart J. 2023 Nov 7:ehad662. doi: 10.1093.
    PubMed     Abstract available
    
    
    
45. SLUIJTER JPG, Xiao J
    Post-translational modifications upon mitochondrial dysfunction in heart failure.
    Eur Heart J. 2023 Nov 6:ehad710. doi: 10.1093.
    PubMed    
    
    
    
46. INCIARDI RM, Solomon SD
    Beyond the rhythm: atrial fibrillation, diastolic dysfunction, and heart failure.
    Eur Heart J. 2023 Nov 3:ehad747. doi: 10.1093.
    PubMed    
    
    
    October 2023
47. RESTIVO A, Paglianiti DA, D'Amario D
    Left atrial pressure-assisted acute heart failure management in the cardiac intensive care unit: a proof-of-concept.
    Eur Heart J. 2023 Oct 26:ehad730. doi: 10.1093.
    PubMed    
    
    
    
48. LIUZZO G, Patrono C
    Moving a STEP forward in the treatment of patients with obesity and heart failure with preserved ejection fraction.
    Eur Heart J. 2023 Oct 25:ehad674. doi: 10.1093.
    PubMed    
    
    
    
49. CREA F
    Innovative trials in heart failure, dyslipidaemias, and sinus node dysfunction.
    Eur Heart J. 2023;44:4203-4207.
    PubMed    
    
    
    
50. PANDEY A, Kolkailah AA, Cosentino F, Cannon CP, et al
    Ertugliflozin and hospitalization for heart failure across the spectrum of pre-trial ejection fraction: post-hoc analyses of the VERTIS CV trial.
    Eur Heart J. 2023 Oct 21:ehad639. doi: 10.1093.
    PubMed    
    
    
    
51. DENIAU B, Costanzo MR, Sliwa K, Asakage A, et al
    Acute heart failure: current pharmacological treatment and perspectives.
    Eur Heart J. 2023 Oct 18:ehad617. doi: 10.1093.
    PubMed     Abstract available
    
    
    
52. PEDICINO D, Volpe M
    Atrial fibrillation ablation improves outcomes in patients with end-stage heart failure: is it all gold the glitter in the CASTLE?
    Eur Heart J. 2023 Oct 17:ehad675. doi: 10.1093.
    PubMed    
    
    
    
53. CAI A, Qiu W, Xia S, Zhou Y, et al
    Sex-specific characteristics and outcomes in hospitalized heart failure with preserved ejection fraction: the China Cardiovascular Association Database-Heart Failure Center Registry.
    Eur Heart J. 2023 Oct 4:ehad619. doi: 10.1093.
    PubMed    
    
    
    
54. CREA F
    Focus on heart failure and cardiomyopathies: new ESC Guidelines and key meta-analyses.
    Eur Heart J. 2023;44:3487-3491.
    PubMed    
    
    
    September 2023
55. BORLAUG BA, Schaff HV, Asirvatham SJ, Koepp KE, et al
    Surgical pericardiotomy to treat heart failure with preserved ejection fraction: a first clinical study.
    Eur Heart J. 2023 Sep 22:ehad620. doi: 10.1093.
    PubMed    
    
    
    
56. MOHANTY S, La Fazia VM, Natale A
    The Antwerp score: is this the 'new hope on the horizon'?
    Eur Heart J. 2023;44:3336-3338.
    PubMed    
    
    
    
57. PANDEY AK, Bhatt DL, Pandey A, Marx N, et al
    Mechanisms of benefits of sodium-glucose cotransporter 2 inhibitors in heart failure with preserved ejection fraction.
    Eur Heart J. 2023 Sep 7:ehad389. doi: 10.1093.
    PubMed     Abstract available
    
    
    
58. CREA F
    Hot topics in congenital heart disease: tetralogy of Fallot, Ross operation, immunodeficiency, cardiac arrest, and end-stage heart failure.
    Eur Heart J. 2023;44:3201-3204.
    PubMed    
    
    
    
59. LADOUCEUR M
    Congenitally corrected transposition of the great arteries: have we shifted the disease 'trajectory?
    Eur Heart J. 2023;44:3292-3294.
    PubMed    
    
    
    
60. ANGERMANN CE, Ertl G
    Remote heart failure management guided by pulmonary artery pressure home monitoring: rewriting the future?
    Eur Heart J. 2023 Sep 6:ehad525. doi: 10.1093.
    PubMed    
    
    
    
61. BROWNELL NK, Fonarow GC
    Hospitalization for heart failure requires a PROMPT response.
    Eur Heart J. 2023 Sep 6:ehad444. doi: 10.1093.
    PubMed    
    
    
    August 2023
62. GHAZI L, Yamamoto Y, Fuery M, O'Connor K, et al
    Electronic health record alerts for management of heart failure with reduced ejection fraction in hospitalized patients: the PROMPT-AHF trial.
    Eur Heart J. 2023 Aug 31:ehad512. doi: 10.1093.
    PubMed     Abstract available
    
    
    
63. LEONG DP, Joseph P, McMurray JJV, Rouleau J, et al
    Frailty and outcomes in heart failure patients from high-, middle- and low-Income countries.
    Eur Heart J. 2023 Aug 28:ehad595. doi: 10.1093.
    PubMed     Abstract available
    
    
    
64. CANNIE DE, Syrris P, Protonotarios A, Bakalakos A, et al
    Emery-Dreifuss Muscular Dystrophy 1 is associated with high risk of malignant ventricular arrhythmias and end-stage heart failure.
    Eur Heart J. 2023 Aug 28:ehad561. doi: 10.1093.
    PubMed     Abstract available
    
    
    
65. MCALISTER FA
    Frailty: A new Vital Sign in Heart Failure Comes of age.
    Eur Heart J. 2023 Aug 28:ehad559. doi: 10.1093.
    PubMed    
    
    
    
66. NASER JA, Lee E, Scott CG, Kennedy AM, et al
    Prevalence and Incidence of Diastolic Dysfunction in Atrial Fibrillation: Clinical Implications.
    Eur Heart J. 2023 Aug 28:ehad592. doi: 10.1093.
    PubMed     Abstract available
    
    
    
67. VARSHNEY AS, Shah M, Vemulapalli S, Kosinski A, et al
    Heart Failure Medical Therapy Prior to Mitral Transcatheter Edge-to-Edge Repair: The STS/ACC Transcatheter Valve Therapy Registry.
    Eur Heart J. 2023 Aug 26:ehad584. doi: 10.1093.
    PubMed     Abstract available
    
    
    
68. MERKELY B, Hatala R, Wranicz JK, Duray G, et al
    Upgrade of right ventricular pacing to cardiac resynchronisation therapy in heart failure: a randomised trial.
    Eur Heart J. 2023 Aug 26:ehad591. doi: 10.1093.
    PubMed     Abstract available
    
    
    
69. LINDE C
    The BUDAPEST trial: a good grade for upgrades in heart failure with reduced ejection fraction.
    Eur Heart J. 2023 Aug 26:ehad588. doi: 10.1093.
    PubMed    
    
    
    
70. PONIKOWSKI P, Mentz RJ, Hernandez AF, Butler J, et al
    Efficacy of Ferric carboxymaltose in heart failure with iron deficiency: an individual patient data meta-analysis.
    Eur Heart J. 2023 Aug 26:ehad586. doi: 10.1093.
    PubMed     Abstract available
    
    
    
71. BUENO H, Packer M
    Acetazolamide for Acute Heart Failure: Is ADVOR a Riddle Wrapped in a Mystery Inside an Enigma?
    Eur Heart J. 2023 Aug 25:ehad560. doi: 10.1093.
    PubMed    
    
    
    
72. MEEKERS E, Dauw J, Martens P, Dhont S, et al
    Renal Function and Decongestion With Acetazolamide in Acute Decompensated Heart Failure: The ADVOR Trial.
    Eur Heart J. 2023 Aug 25:ehad557. doi: 10.1093.
    PubMed     Abstract available
    
    
    
73. MCDONAGH TA, Metra M, Adamo M, Gardner RS, et al
    2023 Focused Update of the 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure.
    Eur Heart J. 2023 Aug 25:ehad195. doi: 10.1093.
    PubMed    
    
    
    
74. WU J, Nadarajah R, Nakao YM, Nakao K, et al
    Temporal trends of cause-specific mortality after diagnosis of atrial fibrillation.
    Eur Heart J. 2023 Aug 25:ehad571. doi: 10.1093.
    PubMed     Abstract available
    
    
    
75. BAUERSACHS J, Soltani S
    Sodium-glucose co-transporter 2 inhibitors and mineralocorticoid receptor antagonists synergism in heart failure: it takes two to tango.
    Eur Heart J. 2023 Aug 23:ehad540. doi: 10.1093.
    PubMed    
    
    
    
76. BANERJEE M, Maisnam I, Pal R, Mukhopadhyay S, et al
    Mineralocorticoid receptor antagonists with sodium-glucose co-transporter-2 inhibitors in heart failure: a meta-analysis.
    Eur Heart J. 2023 Aug 22:ehad522. doi: 10.1093.
    PubMed     Abstract available
    
    
    
77. VAN DISSEL AC, Opotowsky AR, Burchill LJ, Aboulhosn J, et al
    End-stage heart failure in congenitally corrected transposition of the great arteries: a multicentre study.
    Eur Heart J. 2023 Aug 18:ehad511. doi: 10.1093.
    PubMed     Abstract available
    
    
    
78. CREA F
    Late breaking trials in heart failure.
    Eur Heart J. 2023;44:2877-2882.
    PubMed    
    
    
    
79. MARTENS P, Testani J, Damman K
    Prevention and treatment of diuretic resistance in acute heart failure: when to use which combination of diuretics?
    Eur Heart J. 2023;44:2978-2981.
    PubMed    
    
    
    
80. CHENG RK, Cuddy SAM
    Neurohormonal blockade in transthyretin amyloidosis: perhaps one size does not fit all?
    Eur Heart J. 2023;44:2908-2910.
    PubMed    
    
    
    
81. BAYES-GENIS A, Pascual-Figal D
    Making STRONGer the transition phase: personalized GDMT through NT-proBNP monitoring.
    Eur Heart J. 2023;44:2963-2965.
    PubMed    
    
    
    
82. NADARAJAH R, Nakao YM, Wu J, Gale CP, et al
    Using routinely collected health record data for the earlier detection of heart failure with preserved ejection fraction: FIND-HFpEF.
    Eur Heart J. 2023 Aug 3:ehad440. doi: 10.1093.
    PubMed    
    
    
    
83. LIN GM, Tsai KZ, Lavie CJ
    Waist-to-height ratio for the obesity paradox in heart failure: is it a matter of fitness?
    Eur Heart J. 2023 Aug 2:ehad503. doi: 10.1093.
    PubMed    
    
    
    
84. ROHDE LE, McMurray JJV
    REVIV(E)ing the ischaemic paradigm in heart failure: STICHes are needed.
    Eur Heart J. 2023 Aug 1:ehad488. doi: 10.1093.
    PubMed    
    
    
    July 2023
85. PEDICINO D, Volpe M
    New evidence supporting haemodynamics-guided remote management of congestion in heart failure.
    Eur Heart J. 2023 Jul 21:ehad435. doi: 10.1093.
    PubMed    
    
    
    
86. VERGALLO R, Patrono C
    Heart failure and socioeconomic status: global differences and inequalities.
    Eur Heart J. 2023 Jul 15:ehad410. doi: 10.1093.
    PubMed    
    
    
    
87. GREENE SJ, Fonarow GC
    Targeting sacubitril/valsartan for heart failure with mildly reduced or preserved ejection fraction.
    Eur Heart J. 2023 Jul 5:ehad427. doi: 10.1093.
    PubMed    
    
    
    
88. 
    Corrigendum to: Heart failure, peripheral artery disease, and dapagliflozin: a patient-level meta-analysis of DAPA-HF and DELIVER.
    Eur Heart J. 2023 Jul 3:ehad406. doi: 10.1093.
    PubMed    
    
    
    June 2023
89. BERGONTI M, Ascione C, Marcon L, Pambrun T, et al
    Left ventricular functional recovery after atrial fibrillation catheter ablation in heart failure: a prediction model.
    Eur Heart J. 2023 Jun 30:ehad428. doi: 10.1093.
    PubMed     Abstract available
    
    
    
90. KOEHLER F, Hindricks G
    Is telemonitoring for heart failure ready after a journey longer than two decades?
    Eur Heart J. 2023 Jun 27:ehad395. doi: 10.1093.
    PubMed    
    
    
    
91. WITSCH J, Kasner SE
    Redefining the role of heart failure in stroke.
    Eur Heart J. 2023 Jun 26:ehad360. doi: 10.1093.
    PubMed    
    
    
    
92. YANG M, Kondo T, Butt JH, Abraham WT, et al
    Stroke in patients with heart failure and reduced or preserved ejection fraction.
    Eur Heart J. 2023 Jun 26:ehad338. doi: 10.1093.
    PubMed     Abstract available
    
    
    
93. CREA F
    Challenges and opportunities in the management of acute heart failure and cardiac amyloidosis.
    Eur Heart J. 2023;44:2135-2139.
    PubMed    
    
    
    
94. ARNOTT C, Neal B
    Good for your heart and safe for your toes: a patient-level meta-analysis of DAPA-HF and DELIVER.
    Eur Heart J. 2023;44:2184-2186.
    PubMed    
    
    
    
95. TOLOMEO P, Butt JH, Kondo T, Campo G, et al
    Importance of cystatin C in estimating glomerular filtration rate: the PARADIGM-HF trial.
    Eur Heart J. 2023;44:2202-2212.
    PubMed     Abstract available
    
    
    
96. PEDICINO D, Vergallo R
    Long-lasting effects of transcatheter repair of secondary mitral regurgitation: the latest lesson from COAPT trial.
    Eur Heart J. 2023 Jun 14:ehad349. doi: 10.1093.
    PubMed    
    
    
    
97. JANKOWSKA EA, Ponikowski P
    Acyl-ghrelin therapy for heart failure: already a novel inotrope or even more?
    Eur Heart J. 2023;44:2026-2028.
    PubMed    
    
    
    
98. CREA F
    Addressing the pandemic of heart failure: old and new therapeutic opportunities.
    Eur Heart J. 2023;44:1961-1964.
    PubMed    
    
    
    
99. MARTENS P, Verbrugge FH, Dauw J, Nijst P, et al
    Pre-treatment bicarbonate levels and decongestion by acetazolamide: the ADVOR trial.
    Eur Heart J. 2023;44:1995-2005.
    PubMed     Abstract available
    
    
    
100. MAHMOOD SS, Riedell PA, Feldman S, George G, et al
     Biomarkers and cardiovascular outcomes in chimeric antigen receptor T-cell therapy recipients.
     Eur Heart J. 2023;44:2029-2042.
     PubMed     Abstract available
     
     
     
101. MARTENS P, Yu S, Larive B, Borlaug BA, et al
     Iron deficiency in pulmonary vascular disease: pathophysiological and clinical implications.
     Eur Heart J. 2023;44:1979-1991.
     PubMed     Abstract available
     
     
     
102. CAMPBELL RT, Docherty KF
     Serum bicarbonate and congestion: a potential biomarker for identifying and guiding management in diuretic resistance?
     Eur Heart J. 2023;44:2006-2008.
     PubMed    
     
     
     
103. MARX N, Muller-Wieland D
     SGLT2 inhibitors in heart failure and type 2 diabetes: from efficacy in trials towards effectiveness in the real world.
     Eur Heart J. 2023 Jun 8:ehad282. doi: 10.1093.
     PubMed    
     
     
     
104. FU EL, Patorno E, Everett BM, Vaduganathan M, et al
     Sodium-glucose cotransporter 2 inhibitors vs. sitagliptin in heart failure and type 2 diabetes: an observational cohort study.
     Eur Heart J. 2023 Jun 1:ehad273. doi: 10.1093.
     PubMed     Abstract available
     
     
     May 2023
105. 
     Correction to: The year in cardiovascular medicine 2022: the top 10 papers in heart failure and cardiomyopathies.
     Eur Heart J. 2023 May 24:ehad307. doi: 10.1093.
     PubMed    
     
     
     
106. BUTT JH, Kondo T, Yang M, Jhund PS, et al
     Heart failure, peripheral artery disease, and dapagliflozin: a patient-level meta-analysis of DAPA-HF and DELIVER.
     Eur Heart J. 2023 May 23:ehad276. doi: 10.1093.
     PubMed     Abstract available
     
     
     
107. CHATUR S, Vaduganathan M, Claggett B, Vardeny O, et al
     Dapagliflozin and diuretic utilization in heart failure with mildly reduced or preserved ejection fraction: the DELIVER trial.
     Eur Heart J. 2023 May 23:ehad283. doi: 10.1093.
     PubMed     Abstract available
     
     
     
108. BORLAUG BA, Testani JM
     SGLT2 inhibitors and Diuretics in Heart Failure: Clicking Reset on the Renal Volume Setpoint?
     Eur Heart J. 2023 May 23:ehad345. doi: 10.1093.
     PubMed    
     
     
     
109. ADAMO M, Pagnesi M, Mebazaa A, Davison B, et al
     NT-proBNP and high-intensity care for acute heart failure: the STRONG-HF trial.
     Eur Heart J. 2023 May 22:ehad335. doi: 10.1093.
     PubMed     Abstract available
     
     
     
110. IOANNOU A, Massa P, Patel RK, Razvi Y, et al
     Conventional heart failure therapy in cardiac ATTR amyloidosis.
     Eur Heart J. 2023 May 22:ehad347. doi: 10.1093.
     PubMed     Abstract available
     
     
     
111. SCHOLTE NTB, Gurgoze MT, Aydin D, Theuns DAMJ, et al
     Telemonitoring for heart failure: a meta-analysis.
     Eur Heart J. 2023 May 22:ehad280. doi: 10.1093.
     PubMed     Abstract available
     
     
     
112. CLEPHAS PRD, Radhoe SP, Boersma E, Gregson J, et al
     Efficacy of Pulmonary Artery Pressure Monitoring in Patients with Chronic Heart Failure: A Meta-Analysis of Three Randomized Controlled Trials.
     Eur Heart J. 2023 May 21:ehad346. doi: 10.1093.
     PubMed     Abstract available
     
     
     
113. VADUGANATHAN M, Mentz RJ, Claggett BL, Miao ZM, et al
     Sacubitril/valsartan in heart failure with mildly reduced or preserved ejection fraction: a pre-specified participant-level pooled analysis of PARAGLIDE-HF and PARAGON-HF.
     Eur Heart J. 2023 May 21:ehad344. doi: 10.1093.
     PubMed     Abstract available
     
     
     
114. ERN YEOH S, Osmanska J, Petrie MC, Brooksbank KJM, et al
     Dapagliflozin versus metolazone in heart failure resistant to loop diuretics.
     Eur Heart J. 2023 May 21:ehad341. doi: 10.1093.
     PubMed     Abstract available
     
     
     
115. DAMMAN K
     Risk of knowing too much: the tricky case of estimated glomerular filtration rate and treatment decisions in heart failure.
     Eur Heart J. 2023 May 20:ehad284. doi: 10.1093.
     PubMed    
     
     
     
116. MULLENS W, Schulze PC, Westphal J, Bogoviku J, et al
     Great debate: in patients with decompensated heart failure, acetazolamide in addition to loop diuretics is the first choice.
     Eur Heart J. 2023 May 19:ehad266. doi: 10.1093.
     PubMed    
     
     
     
117. 
     Corrigendum to: Reduced lean body mass: a potential modifiable contributor to the pathophysiology of heart failure.
     Eur Heart J. 2023 May 8:ehad272. doi: 10.1093.
     PubMed    
     
     
     
118. CREA F
     Heart failure with preserved ejection fraction: innovative diagnostic approaches and therapeutic targets.
     Eur Heart J. 2023;44:1481-1485.
     PubMed    
     
     
     
119. LEHTONEN J, Uusitalo V, Poyhonen P, Mayranpaa MI, et al
     Cardiac sarcoidosis: phenotypes, diagnosis, treatment, and prognosis.
     Eur Heart J. 2023;44:1495-1510.
     PubMed     Abstract available
     
     
     
120. LEE SY, Chang S, Youn JC
     Successful management of aortic root thrombosis in a patient with Heartmate 3.
     Eur Heart J. 2023;44:1578.
     PubMed    
     
     
     April 2023
121. XIN Y, Li J, Li H
     Combination diuretic therapy in acute heart failure.
     Eur Heart J. 2023 Apr 21:ehad189. doi: 10.1093.
     PubMed    
     
     
     
122. TRULLAS JC, Casado J, Morales-Rull JL
     Combination diuretic therapy in acute heart failure.
     Eur Heart J. 2023 Apr 21:ehad217. doi: 10.1093.
     PubMed    
     
     
     
123. 
     Erratum to: Iron deficiency in heart failure across the spectrum of left ventricular ejection fraction: dotting the i's.
     Eur Heart J. 2023 Apr 20:ehad232. doi: 10.1093.
     PubMed    
     
     
     
124. JALLOH MB, Granger CB, Fonarow GC, Van Spall HGC, et al
     Multi-level implementation strategies to improve uptake of evidence-based therapies in heart failure.
     Eur Heart J. 2023 Apr 15:ehad150. doi: 10.1093.
     PubMed    
     
     
     
125. SHERROD CF, Farr SL, Sauer AJ
     Overcoming treatment inertia for patients with heart failure: how do we build systems that move us from rest to motion?
     Eur Heart J. 2023 Apr 12:ehad169. doi: 10.1093.
     PubMed    
     
     
     
126. VAN VELDHUISEN DJ, Bauersachs J
     Digitalis in heart failure: declining use and ongoing outcome trials.
     Eur Heart J. 2023 Apr 8:ehad185. doi: 10.1093.
     PubMed    
     
     
     
127. CREA F
     The link among heart failure, chronic kidney disease, and cancer: new light shed on the complex patient.
     Eur Heart J. 2023;44:1099-1102.
     PubMed    
     
     
     March 2023
128. LAM CSP, Ho JE
     Do we need dedicated heart failure with preserved ejection fraction clinics?
     Eur Heart J. 2023 Mar 29:ehad172. doi: 10.1093.
     PubMed    
     
     
     
129. SATO R, von Haehling S
     Revisiting the obesity paradox in heart failure: what is the best anthropometric index to gauge obesity?
     Eur Heart J. 2023 Mar 22:ehad079. doi: 10.1093.
     PubMed    
     
     
     
130. BUTT JH, Petrie MC, Jhund PS, Sattar N, et al
     Anthropometric measures and adverse outcomes in heart failure with reduced ejection fraction: revisiting the obesity paradox.
     Eur Heart J. 2023 Mar 22:ehad083. doi: 10.1093.
     PubMed     Abstract available
     
     
     
131. PACKER M, Siddiqi TJ, Butler J
     Drugs that slow the progression of diabetic kidney disease: are renoprotective effects attenuated in heart failure?
     Eur Heart J. 2023 Mar 21:ehad158. doi: 10.1093.
     PubMed    
     
     
     
132. LIUZZO G, Volpe M
     TRANSFORM-HF closes the loop on diuretic therapy in heart failure.
     Eur Heart J. 2023 Mar 21:ehad124. doi: 10.1093.
     PubMed    
     
     
     
133. DIAZ-CANESTRO C, Ng HF, Yiu KH, Montero D, et al
     Reduced lean body mass: a potential modifiable contributor to the pathophysiology of heart failure.
     Eur Heart J. 2023 Mar 16:ehad130. doi: 10.1093.
     PubMed    
     
     
     
134. VERWERFT J, Soens L, Wynants J, Meysman M, et al
     Heart failure with preserved ejection fraction: relevance of a dedicated dyspnoea clinic.
     Eur Heart J. 2023 Mar 16:ehad141. doi: 10.1093.
     PubMed     Abstract available
     
     
     
135. PEDICINO D, Volpe M
     Improving care for heart failure patients by COACHing clinicians to use decision-support tools.
     Eur Heart J. 2023 Mar 16:ehad097. doi: 10.1093.
     PubMed    
     
     
     
136. RAO VN, Giczewska A, Chiswell K, Felker GM, et al
     Long-term outcomes of phenoclusters in severe tricuspid regurgitation.
     Eur Heart J. 2023 Mar 16:ehad133. doi: 10.1093.
     PubMed     Abstract available
     
     
     
137. LUND LH, Hage C, Pironti G, Thorvaldsen T, et al
     Acyl ghrelin improves cardiac function in heart failure and increases fractional shortening in cardiomyocytes without calcium mobilization.
     Eur Heart J. 2023 Mar 14:ehad100. doi: 10.1093.
     PubMed     Abstract available
     
     
     
138. TAYLOR RS, Dalal HM, Zwisler AD
     Cardiac rehabilitation for heart failure: 'Cinderella' or evidence-based pillar of care?
     Eur Heart J. 2023 Mar 11:ehad118. doi: 10.1093.
     PubMed     Abstract available
     
     
     
139. VERELST FR, Van Craenenbroeck EM, Gevaert AB
     Iron deficiency in heart failure across the spectrum of left ventricular ejection fraction: dotting the i's.
     Eur Heart J. 2023 Mar 9:ehad131. doi: 10.1093.
     PubMed    
     
     
     
140. SHEMESH E, Chevli PA, Islam T, German CA, et al
     Circulating ketone bodies and cardiovascular outcomes: the MESA study.
     Eur Heart J. 2023 Mar 6:ehad087. doi: 10.1093.
     PubMed     Abstract available
     
     
     
141. KAPELIOS CJ, Benson L, Crespo-Leiro MG, Anker SD, et al
     Participation in a clinical trial is associated with lower mortality but not lower risk of HF hospitalization in patients with heart failure: observations from the ESC EORP Heart Failure Long-Term Registry.
     Eur Heart J. 2023 Mar 4:ehad109. doi: 10.1093.
     PubMed    
     
     
     February 2023
142. CREA F
     Heart failure: from pathophysiology to deep learning-based outcome prediction.
     Eur Heart J. 2023;44:629-632.
     PubMed    
     
     
     
143. VOLPE M, Gallo G, Rubattu S
     Endocrine functions of the heart: from bench to bedside.
     Eur Heart J. 2023;44:643-655.
     PubMed     Abstract available
     
     
     
144. WOUTERS PC, van de Leur RR, Vessies MB, van Stipdonk AMW, et al
     Electrocardiogram-based deep learning improves outcome prediction following cardiac resynchronization therapy.
     Eur Heart J. 2023;44:680-692.
     PubMed     Abstract available
     
     
     
145. GAUTAM N, Mounsey JP, Yeh ETH, Al'Aref SJ, et al
     Promises and challenges of machine learning for device therapy in heart failure.
     Eur Heart J. 2023 Feb 18:ehad036. doi: 10.1093.
     PubMed    
     
     
     
146. VERGALLO R, Pedicino D
     Intravenous ferric derisomaltose for patients with heart failure: does iron heart translate into IRONMAN?
     Eur Heart J. 2023 Feb 14:ehad076. doi: 10.1093.
     PubMed    
     
     
     
147. 
     Corrigendum to: Data standards for heart failure: the European Unified Registries for Heart Care Evaluation and Randomized Trials (EuroHeart).
     Eur Heart J. 2023 Feb 14:ehad059. doi: 10.1093.
     PubMed    
     
     
     
148. 
     Corrigendum to: Heart Failure Association/European Society of Cardiology Atlas second edition: new insights into understanding the burden of heart failure.
     Eur Heart J. 2023 Feb 3:ehad060. doi: 10.1093.
     PubMed    
     
     
     
149. CREA F
     Epidemiology and treatment of acute and chronic heart failure.
     Eur Heart J. 2023;44:329-332.
     PubMed    
     
     
     
150. GERSH BJ, De Mets D
     Revascularization in ischaemic cardiomyopathy: how to interpret current evidence.
     Eur Heart J. 2023;44:365-367.
     PubMed    
     
     
     January 2023
151. ZHANG T, Yang X, Song J, Shi Y, et al
     Emergent transcatheter aortic valve implantation combined with enterectomy for acute decompensated heart failure caused by severe aortic stenosis and strangulated femoral hernia.
     Eur Heart J. 2023 Jan 26:ehad007. doi: 10.1093.
     PubMed    
     
     
     
152. 
     Corrigendum to: Investigator-reported ventricular arrhythmias and mortality in heart failure with mildly reduced or preserved ejection fraction.
     Eur Heart J. 2023 Jan 24:ehad045. doi: 10.1093.
     PubMed    
     
     
     
153. BRUHN J, Malmborg M, Garred CH, Ravn P, et al
     Temporal trends in the incidence of malignancy in heart failure: a nationwide Danish study.
     Eur Heart J. 2023 Jan 24:ehac797. doi: 10.1093.
     PubMed     Abstract available
     
     
     
154. AMERI P, Bertero E, Meijers WC
     Cancer is a comorbidity of heart failure.
     Eur Heart J. 2023 Jan 24:ehac710. doi: 10.1093.
     PubMed    
     
     
     
155. MARK PB, Carrero JJ, Matsushita K, Sang Y, et al
     Major cardiovascular events and subsequent risk of kidney failure with replacement therapy: a CKD Prognosis Consortium study.
     Eur Heart J. 2023 Jan 24:ehac825. doi: 10.1093.
     PubMed     Abstract available
     
     
     
156. KATO ET, Morrow DA, Guo J, Berg DD, et al
     Growth differentiation factor 15 and cardiovascular risk: individual patient meta-analysis.
     Eur Heart J. 2023;44:293-300.
     PubMed     Abstract available
     
     
     
157. WALDMANN V, Barra S, Marijon E
     Ventricular arrhythmias and sudden cardiac death in heart failure with mildly reduced or preserved ejection fraction: knowledge gaps.
     Eur Heart J. 2023 Jan 20:ehad001. doi: 10.1093.
     PubMed    
     
     
     
158. PEDICINO D, Volpe M
     Influenza vaccine for heart failure patients in low- and middle-income countries: another piece in the puzzle.
     Eur Heart J. 2023 Jan 14:ehac809. doi: 10.1093.
     PubMed    
     
     
     
159. CURTAIN JP, Adamson C, Kondo T, Butt J, et al
     Investigator-reported ventricular arrhythmias and mortality in heart failure with mildly reduced or preserved ejection fraction.
     Eur Heart J. 2023 Jan 12:ehac801. doi: 10.1093.
     PubMed     Abstract available
     
     
     
160. DE BOER RA, Bauersachs J
     The year in cardiovascular medicine 2022: the top 10 papers in heart failure and cardiomyopathies.
     Eur Heart J. 2023 Jan 2:ehac781. doi: 10.1093.
     PubMed    
     
     
     
161. CREA F
     Acute and chronic heart failure: exciting therapeutic perspectives.
     Eur Heart J. 2023;44:1-4.
     PubMed    
     
     
     
162. SAVARESE G, von Haehling S, Butler J, Cleland JGF, et al
     Iron deficiency and cardiovascular disease.
     Eur Heart J. 2023;44:14-27.
     PubMed     Abstract available
     
     
     December 2022
163. ZAKERI R, Wilson DG, Mohammed SF
     Time to revisit combination loop and thiazide diuretic therapy for patients with acute heart failure.
     Eur Heart J. 2022 Dec 30:ehac784. doi: 10.1093.
     PubMed    
     
     
     
164. OLIVOTTO I, Udelson JE, Pieroni M, Rapezzi C, et al
     Genetic causes of heart failure with preserved ejection fraction: emerging pharmacological treatments.
     Eur Heart J. 2022 Dec 30:ehac764. doi: 10.1093.
     PubMed     Abstract available
     
     
     
165. CREA F
     Focus on trials: dementia, lipids, thrombosis, and heart failure.
     Eur Heart J. 2022;43:4965-4969.
     PubMed    
     
     
     
166. CRESPO-LEIRO MG, McDonagh TA, Barge-Caballero E
     Omecamtiv mecarbil for patients with severe systolic dysfunction and hypotension.
     Eur Heart J. 2022;43:5017-5019.
     PubMed    
     
     
     
167. SCHAUFELBERGER M, Basic C
     Increasing incidence of heart failure among young adults: how can we stop it?
     Eur Heart J. 2022 Dec 20:ehac730. doi: 10.1093.
     PubMed    
     
     
     
168. DOCHERTY KF, Jhund PS
     A welcome 'failure' of gliflozins: blood pressure reduction in heart failure.
     Eur Heart J. 2022 Dec 14:ehac712. doi: 10.1093.
     PubMed    
     
     
     
169. 
     Corrigendum to: HFp2EF: heart failure with pulmonary dysfunction and preserved ejection fraction?
     Eur Heart J. 2022 Dec 12:ehac766. doi: 10.1093.
     PubMed    
     
     
     
170. BOHM M, Anker S, Mahfoud F, Lauder L, et al
     Empagliflozin, irrespective of blood pressure, improves outcomes in heart failure with preserved ejection fraction: the EMPEROR-Preserved trial.
     Eur Heart J. 2022 Dec 7:ehac693. doi: 10.1093.
     PubMed     Abstract available
     
     
     
171. EL-CHOULI M, Meddis A, Christensen DM, Gerds TA, et al
     Lifetime risk of comorbidity in patients with simple congenital heart disease: a Danish nationwide study.
     Eur Heart J. 2022 Dec 7:ehac727. doi: 10.1093.
     PubMed     Abstract available
     
     
     
172. LECOEUR E, Domenge O, Fayol A, Jannot AS, et al
     Epidemiology of heart failure in young adults: a French nationwide cohort study.
     Eur Heart J. 2022 Dec 1:ehac651. doi: 10.1093.
     PubMed     Abstract available
     
     
     
173. NAGALINGAM RS, Chattopadhyaya S, Al-Hattab DS, Cheung DYC, et al
     Scleraxis and fibrosis in the pressure-overloaded heart.
     Eur Heart J. 2022;43:4739-4750.
     PubMed     Abstract available
     
     
     November 2022
174. SCOTTI A, Coisne A, Taramasso M, Granada JF, et al
     Sex-Related Characteristics and Short-Term Outcomes of Patients Undergoing Transcatheter Tricuspid Valve Intervention for Tricuspid Regurgitation.
     Eur Heart J. 2022 Nov 29:ehac735. doi: 10.1093.
     PubMed     Abstract available
     
     
     
175. HAXHA S, Halili A, Malmborg M, Pedersen-Bjergaard U, et al
     Type 2 diabetes mellitus and higher rate of complete atrioventricular block: a Danish Nationwide Registry.
     Eur Heart J. 2022 Nov 26:ehac662. doi: 10.1093.
     PubMed     Abstract available
     
     
     
176. MEBAZAA A, Solal AC, Colombo PC
     Assessing and treating congestion in acute decompensated heart failure: are we seeing the light at the end of the tunnel?
     Eur Heart J. 2022 Nov 25:ehac680. doi: 10.1093.
     PubMed    
     
     
     
177. TRULLAS JC, Morales-Rull JL, Casado J, Carrera-Izquierdo M, et al
     Combining loop with thiazide diuretics for decompensated heart failure: the CLOROTIC trial.
     Eur Heart J. 2022 Nov 24:ehac689. doi: 10.1093.
     PubMed     Abstract available
     
     
     
178. WANG B, Lee RJ, Tao L
     First-in-human transcatheter endocardial alginate-hydrogel implantation for the treatment of heart failure.
     Eur Heart J. 2022 Nov 24:ehac671. doi: 10.1093.
     PubMed    
     
     
     
179. VOLPE M, Patrono C
     Benefits of SGLT2i in heart failure across a broad range of ejection fractions: new opportunities and future challenges.
     Eur Heart J. 2022 Nov 12. pii: 6825243. doi: 10.1093.
     PubMed    
     
     
     
180. PUGLIESE NR, Masi S, Taddei S
     Rethinking albuminuria as a marker to drive treatment in congestive heart failure.
     Eur Heart J. 2022 Nov 12. pii: 6825227. doi: 10.1093.
     PubMed    
     
     
     
181. PATHAK S, Lai FY, Miksza J, Petrie MC, et al
     Surgical or Percutaneous Coronary Revascularisation for Heart Failure: An In Silico Model using Routinely Collected Health Data to Emulate a Clinical Trial.
     Eur Heart J. 2022 Nov 9. pii: 6815617. doi: 10.1093.
     PubMed     Abstract available
     
     
     
182. GUTMANN C, Zelniker TA, Mayr M
     SGLT2 inhibitors in heart failure: insights from plasma proteomics.
     Eur Heart J. 2022 Nov 7. pii: 6808669. doi: 10.1093.
     PubMed    
     
     
     
183. OMOTE K, Borlaug BA
     Pulmonary vascular reserve with exercise in heart failure.
     Eur Heart J. 2022;43:4516-4517.
     PubMed    
     
     
     
184. CREA F
     Heart failure in cardio-oncology and adult congenital heart disease: new challenges and therapeutic targets.
     Eur Heart J. 2022;43:4443-4446.
     PubMed    
     
     
     
185. ANKER SD, Usman MS, Butler J
     'Normal weight' is really not normal in chronic disease.
     Eur Heart J. 2022;43:4418-4420.
     PubMed    
     
     
     October 2022
186. PEDICINO D, Volpe M
     From the management of altitude sickness to treatment of congestion in acute heart failure: a new season for acetazolamide?
     Eur Heart J. 2022 Oct 26. pii: 6773465. doi: 10.1093.
     PubMed    
     
     
     
187. JASTRZEBSKI M, Kielbasa G, Cano O, Curila K, et al
     Left bundle branch area pacing outcomes: the multicentre European MELOS study.
     Eur Heart J. 2022;43:4161-4173.
     PubMed     Abstract available
     
     
     
188. TORBATI T, Shufelt C, Wei J, Noel Bairey Merz C, et al
     Premature menopause and cardiovascular disease: can we blame estrogen?
     Eur Heart J. 2022;43:4158-4160.
     PubMed    
     
     
     
189. BIEGUS J, Voors AA, Collins SP, Kosiborod MN, et al
     Impact of empagliflozin on decongestion in acute heart failure: the EMPULSE trial.
     Eur Heart J. 2022 Oct 18. pii: 6762535. doi: 10.1093.
     PubMed     Abstract available
     
     
     
190. BAKRIS GL, Jaisser F
     Aldosterone excess and cardiorenal risk: more common than appreciated.
     Eur Heart J. 2022;43:3792-3793.
     PubMed    
     
     
     
191. SEFEROVIC PM, Rosano GMC, Vardas P, Milinkovic I, et al
     Heart Failure Association/European Society of Cardiology Atlas second edition: new insights into understanding the burden of heart failure.
     Eur Heart J. 2022 Oct 6. pii: 6750021. doi: 10.1093.
     PubMed    
     
     
     September 2022
192. VOLPE M, Pedicino D
     SGLT2 inhibitors DELIVER benefits in heart failure independently of ejection fraction and diabetes: end of the line or need for new studies?
     Eur Heart J. 2022 Sep 29. pii: 6731084. doi: 10.1093.
     PubMed    
     
     
     
193. BOORSMA EM, Ter Maaten JM, Damman K, van Essen BJ, et al
     Albuminuria as a marker of systemic congestion in patients with heart failure.
     Eur Heart J. 2022 Sep 23. pii: 6711732. doi: 10.1093.
     PubMed     Abstract available
     
     
     
194. NABETA T, Kitai T, Naruse Y, Taniguchi T, et al
     Risk stratification of patients with cardiac sarcoidosis: the ILLUMINATE-CS registry.
     Eur Heart J. 2022;43:3450-3459.
     PubMed     Abstract available
     
     
     
195. MESSERLI FH, O'Donnell M, Mente A, Yusuf S, et al
     Settling the controversy of salt substitutes and stroke: sodium reduction or potassium increase?
     Eur Heart J. 2022;43:3365-3367.
     PubMed    
     
     
     
196. LUFT FC
     Translating plasma sodium, stores, and hydration state from mouse to man.
     Eur Heart J. 2022;43:3349-3351.
     PubMed    
     
     
     
197. LUEDIKE P, Heusch G, Rassaf T
     The RUHR Heart Failure Network: improved heart failure care in a metropolitan area.
     Eur Heart J. 2022 Sep 2. pii: 6687152. doi: 10.1093.
     PubMed    
     
     
     August 2022
198. HARRINGTON J, Anker S, Butler J
     Putting the Puzzle Together: SGLT2 Inhibitors from Prevention to Treatment of Heart Failure.
     Eur Heart J. 2022 Aug 29. pii: 6677316. doi: 10.1093.
     PubMed    
     
     
     
199. VON LEWINSKI D, Kolesnik E, Tripolt NJ, Pferschy PN, et al
     Empagliflozin in acute Myocardial Infarction: the EMMY trial.
     Eur Heart J. 2022 Aug 29. pii: 6677315. doi: 10.1093.
     PubMed     Abstract available
     
     
     
200. ADAMSON C, Kondo T, Jhund P, de Boer RA, et al
     Dapagliflozin for heart failure according to body mass index: the DELIVER trial.
     Eur Heart J. 2022 Aug 27. pii: 6674666. doi: 10.1093.
     PubMed     Abstract available
     
     
     
201. ZANNAD F, Ferreira JP, Butler J, Filippatos G, et al
     Effect of Empagliflozin on Circulating Proteomics in Heart Failure: Mechanistic Insights from the EMPEROR Program.
     Eur Heart J. 2022 Aug 26. pii: 6676779. doi: 10.1093.
     PubMed     Abstract available
     
     
     
202. KONDO T, Abdul-Rahim AH, Talebi A, Abraham WT, et al
     Predicting stroke in heart failure and reduced ejection fraction without atrial fibrillation.
     Eur Heart J. 2022 Aug 26. pii: 6676501. doi: 10.1093.
     PubMed     Abstract available
     
     
     
203. SAGRIS D, Shantsila E, Lip GYH
     Stroke risk stratification in patients with heart failure and sinus rhythm.
     Eur Heart J. 2022 Aug 26. pii: 6676507. doi: 10.1093.
     PubMed    
     
     
     
204. WENZEL P
     Thromboinflammation in cardiovascular disease: lessons learned for the management of hypertension, heart failure, and aortic valve stenosis.
     Eur Heart J. 2022 Aug 18. pii: 6671020. doi: 10.1093.
     PubMed    
     
     
     
205. PITT B, Bhatt DL, Metra M
     Does SGLT1 inhibition add to the benefits of SGLT2 inhibition in the prevention and treatment of heart failure?
     Eur Heart J. 2022 Aug 18. pii: 6670977. doi: 10.1093.
     PubMed    
     
     
     
206. CREA F
     The far-reaching beneficial effects of sodium-glucose co-transporter 2 inhibitors in heart failure.
     Eur Heart J. 2022;43:2907-2910.
     PubMed    
     
     
     
207. PANDEY AK, Bhatt DL, Cosentino F, Marx N, et al
     Non-steroidal mineralocorticoid receptor antagonists in cardiorenal disease.
     Eur Heart J. 2022;43:2931-2945.
     PubMed     Abstract available
     
     
     
208. OYAMA K, Raz I, Cahn A, Kuder J, et al
     Obesity and effects of dapagliflozin on cardiovascular and renal outcomes in patients with type 2 diabetes mellitus in the DECLARE-TIMI 58 trial.
     Eur Heart J. 2022;43:2958-2967.
     PubMed     Abstract available
     
     
     
209. MACKENZIE IS, MacDonald TM
     Serum uric acid lowering with empagliflozin in heart failure with reduced ejection fraction: a sweet added benefit?
     Eur Heart J. 2022 Aug 8. pii: 6658201. doi: 10.1093.
     PubMed    
     
     
     
210. PONIKOWSKI P, Biegus J
     Empagliflozin in patients hospitalized for acute heart failure.
     Eur Heart J. 2022 Aug 8. pii: 6658198. doi: 10.1093.
     PubMed    
     
     
     
211. SHIN J, Han K, Jung JH, Park HJ, et al
     Age at menopause and risk of heart failure and atrial fibrillation: a nationwide cohort study.
     Eur Heart J. 2022 Aug 4. pii: 6646730. doi: 10.1093.
     PubMed     Abstract available
     
     
     
212. DACHS TM, Duca F, Rettl R, Binder-Rodriguez C, et al
     Riociguat in pulmonary hypertension and heart failure with preserved ejection fraction: the haemoDYNAMIC trial.
     Eur Heart J. 2022 Aug 1. pii: 6652608. doi: 10.1093.
     PubMed     Abstract available
     
     
     
213. BAUERSACHS J, Olsson KM
     Targeting pulmonary hypertension in patients with heart failure and preserved ejection fraction: rather static than DYNAMIC development?
     Eur Heart J. 2022 Aug 1. pii: 6652609. doi: 10.1093.
     PubMed    
     
     
     July 2022
214. BUTLER J, Anker SD, Lund LH, Coats AJS, et al
     Patiromer for the management of hyperkalemia in heart failure with reduced ejection fraction: the DIAMOND trial.
     Eur Heart J. 2022 Jul 28. pii: 6651164. doi: 10.1093.
     PubMed     Abstract available
     
     
     
215. PACKER M
     Potassium Binders for Patients With Heart Failure? The Real Enlightenment of the DIAMOND Trial.
     Eur Heart J. 2022 Jul 28. pii: 6651163. doi: 10.1093.
     PubMed    
     
     
     
216. VERGALLO R, Volpe M
     Deciphering a decision support tool (CoDE-HF) to improve the diagnosis of acute heart failure.
     Eur Heart J. 2022 Jul 22. pii: 6648207. doi: 10.1093.
     PubMed    
     
     
     
217. 
     Corrigendum to: Empagliflozin and serum potassium in heart failure: an analysis from EMPEROR-Pooled.
     Eur Heart J. 2022 Jul 22. pii: 6649203. doi: 10.1093.
     PubMed    
     
     
     
218. CREA F
     Heart failure: how to optimize guideline-directed medical therapy.
     Eur Heart J. 2022;43:2533-2537.
     PubMed    
     
     
     
219. HADWIGER M, Dagres N, Haug J, Wolf M, et al
     Survival of patients undergoing cardiac resynchronization therapy with or without defibrillator: the RESET-CRT project.
     Eur Heart J. 2022;43:2591-2599.
     PubMed     Abstract available
     
     
     
220. GARG P, Gosling R, Swoboda P, Jones R, et al
     Cardiac magnetic resonance identifies raised left ventricular filling pressure: prognostic implications.
     Eur Heart J. 2022;43:2511-2522.
     PubMed     Abstract available
     
     
     
221. OMOTE K, Sorimachi H, Obokata M, Reddy YNV, et al
     Pulmonary vascular disease in pulmonary hypertension due to left heart disease: pathophysiologic implications.
     Eur Heart J. 2022 Jul 7. pii: 6633254. doi: 10.1093.
     PubMed     Abstract available
     
     
     
222. DOEHNER W, Anker SD, Butler J, Zannad F, et al
     Uric acid and sodium-glucose cotransporter-2 inhibition with empagliflozin in heart failure with reduced ejection fraction: the EMPEROR-reduced trial.
     Eur Heart J. 2022 Jul 5. pii: 6631286. doi: 10.1093.
     PubMed     Abstract available
     
     
     June 2022
223. GOYAL P, Kim M, Krishnan U, Mccullough SA, et al
     Post-operative atrial fibrillation and risk of heart failure hospitalization.
     Eur Heart J. 2022 Jun 28. pii: 6617280. doi: 10.1093.
     PubMed     Abstract available
     
     
     
224. MIDDELDORP ME, Albert CM
     Post-operative AF and heart failure hospitalizations: what remains hidden in patients undergoing surgery.
     Eur Heart J. 2022 Jun 28. pii: 6617281. doi: 10.1093.
     PubMed    
     
     
     
225. TROMP J, Voors AA
     Heart failure medication: moving from evidence generation to implementation.
     Eur Heart J. 2022 Jun 27. pii: 6618448. doi: 10.1093.
     PubMed    
     
     
     
226. RAMLAKHAN KP, Malhame I, Marelli A, Rutz T, et al
     Hypertensive disorders of pregnant women with heart disease: the ESC EORP ROPAC Registry.
     Eur Heart J. 2022 Jun 21. pii: 6612238. doi: 10.1093.
     PubMed     Abstract available
     
     
     
227. 
     Erratum to: Influence of atrial fibrillation on efficacy and safety of omecamtiv mecarbil in heart failure: the GALACTIC-HF trial.
     Eur Heart J. 2022 Jun 18. pii: 6610027. doi: 10.1093.
     PubMed    
     
     
     
228. CREA F
     The complex link among heart failure, atrial fibrillation, and lung diseases, and an update on cardiac transplantation.
     Eur Heart J. 2022;43:2165-2169.
     PubMed    
     
     
     
229. VERMA S, Dhingra NK, Pandey AK, Cosentino F, et al
     Emerging role for SGLT2 inhibitors in mitigating the risk of hyperkalaemia in heart failure.
     Eur Heart J. 2022 Jun 10. pii: 6604931. doi: 10.1093.
     PubMed    
     
     
     
230. FERREIRA JP, Zannad F, Butler J, Filipattos G, et al
     Empagliflozin and serum potassium in heart failure: an analysis from EMPEROR-Pooled.
     Eur Heart J. 2022 Jun 10. pii: 6605266. doi: 10.1093.
     PubMed     Abstract available
     
     
     
231. BRAUNWALD E
     Cardiac xenotransplantation: a new path for the treatment of advanced heart failure?
     Eur Heart J. 2022 Jun 4. pii: 6601572. doi: 10.1093.
     PubMed    
     
     
     
232. PABEL S, Sossalla S
     Atrial fibrillation and heart failure: novel insights into the chicken and egg dilemma.
     Eur Heart J. 2022 Jun 2. pii: 6599046. doi: 10.1093.
     PubMed    
     
     
     May 2022
233. METRA M, Pagnesi M, Claggett BL, Diaz R, et al
     Effects of omecamtiv mecarbil in heart failure with reduced ejection fraction according to blood pressure: the GALACTIC-HF trial.
     Eur Heart J. 2022 May 22. pii: 6590348. doi: 10.1093.
     PubMed     Abstract available
     
     
     
234. CREA F
     Challenges in heart failure: from actionability of genetic variants in cardiopmyopathies to new therapeutic targets.
     Eur Heart J. 2022;43:1887-1890.
     PubMed    
     
     
     
235. VAN VELDHUISEN SL, Gorter TM, van Woerden G, de Boer RA, et al
     Bariatric surgery and cardiovascular disease: a systematic review and meta-analysis.
     Eur Heart J. 2022;43:1955-1969.
     PubMed     Abstract available
     
     
     
236. PARK N, Marquez J, Pham TK, Ko TH, et al
     Cereblon contributes to cardiac dysfunction by degrading Cav1.2alpha.
     Eur Heart J. 2022;43:1973-1989.
     PubMed     Abstract available
     
     
     
237. BECHER PM, Lund LH, Coats AJS, Savarese G, et al
     An update on global epidemiology in heart failure.
     Eur Heart J. 2022 May 17. pii: 6586676. doi: 10.1093.
     PubMed    
     
     
     
238. BARITUSSIO A, Muthurangu V
     Cardiovascular magnetic resonance for the assessment of left ventricular filling pressure in heart failure.
     Eur Heart J. 2022 May 16. pii: 6586208. doi: 10.1093.
     PubMed    
     
     
     
239. ZHU Y, Ackers-Johnson M, Foo R
     T cells: a 'hidden corner' to be explored for treating heart failure.
     Eur Heart J. 2022 May 13. pii: 6585106. doi: 10.1093.
     PubMed    
     
     
     
240. FRANTZ S, Hundertmark MJ, Schulz-Menger J, Bengel FM, et al
     Left ventricular remodelling post-myocardial infarction: pathophysiology, imaging, and novel therapies.
     Eur Heart J. 2022 May 4. pii: 6578707. doi: 10.1093.
     PubMed     Abstract available
     
     
     
241. LINDE C
     CRT-P or CRT-D in heart failure patients: the RESET-CRT project-a prelude to the randomized controlled RESET-CRT study.
     Eur Heart J. 2022 May 3. pii: 6577069. doi: 10.1093.
     PubMed    
     
     
     
242. COWIE MR, Cleland JGF
     The COVID-19 pandemic and heart failure: lessons from GUIDE-HF.
     Eur Heart J. 2022 May 2. pii: 6576548. doi: 10.1093.
     PubMed    
     
     
     
243. TRIBOUILLOY C, Bohbot Y, Kubala M, Ruschitzka F, et al
     Characteristics, management, and outcomes of patients with multiple native valvular heart disease: a substudy of the EURObservational Research Programme Valvular Heart Disease II Survey.
     Eur Heart J. 2022 May 2. pii: 6576528. doi: 10.1093.
     PubMed     Abstract available
     
     
     April 2022
244. ECKHARDT CM, Balte PP, Barr RG, Bertoni AG, et al
     Lung function impairment and risk of incident heart failure: the NHLBI Pooled Cohorts Study.
     Eur Heart J. 2022 Apr 25. pii: 6573769. doi: 10.1093.
     PubMed     Abstract available
     
     
     
245. SHEN L, Jhund PS, Docherty KF, Vaduganathan M, et al
     Accelerated and personalized therapy for heart failure with reduced ejection fraction.
     Eur Heart J. 2022 Apr 25. pii: 6573857. doi: 10.1093.
     PubMed     Abstract available
     
     
     
246. MARON BA, Humbert M
     HFp2EF: heart failure with pulmonary dysfunction and preserved ejection fraction?
     Eur Heart J. 2022 Apr 25. pii: 6573597. doi: 10.1093.
     PubMed    
     
     
     
247. AKTAA S, Batra G, Cleland JGF, Coats A, et al
     Data standards for heart failure: the European Unified Registries for Heart Care Evaluation and Randomized Trials (EuroHeart).
     Eur Heart J. 2022 Apr 20. pii: 6571493. doi: 10.1093.
     PubMed     Abstract available
     
     
     
248. VERBRUGGE FH, Borlaug BA
     Heart failure with normal natriuretic peptide levels: more fat, and that is the main problem.
     Eur Heart J. 2022 Apr 20. pii: 6571179. doi: 10.1093.
     PubMed    
     
     
     
249. VAN DER MEER P, Rienstra M, van Veldhuisen DJ
     A deleterious interaction between omecamtiv mecarbil and atrial fibrillation in patients with heart failure: an influence of digoxin?
     Eur Heart J. 2022 Apr 20. pii: 6571185. doi: 10.1093.
     PubMed    
     
     
     
250. OLIVELLA A, Mendez AB, Ferreira-Gonzalez I
     Mixing the fat with water: are normal natriuretic peptide heart failure with preserved ejection fraction patients just more obese?
     Eur Heart J. 2022 Apr 20. pii: 6571173. doi: 10.1093.
     PubMed    
     
     
     
251. CRESPO-LEIRO MG, Costanzo MR, Gustafsson F, Khush KK, et al
     Heart transplantation: focus on donor recovery strategies, left ventricular assist devices, and novel therapies.
     Eur Heart J. 2022 Apr 20. pii: 6571226. doi: 10.1093.
     PubMed     Abstract available
     
     
     
252. HONG S, Kim KS, Han K, Park CY, et al
     Acromegaly and cardiovascular outcomes: a cohort study.
     Eur Heart J. 2022;43:1491-1499.
     PubMed     Abstract available
     
     
     
253. WACHTER R, Rommel KP
     Hospitalization for heart failure: a window of opportunity.
     Eur Heart J. 2022 Apr 13. pii: 6568144. doi: 10.1093.
     PubMed    
     
     
     
254. TROMP J, Ouwerkerk W, Teng TK, Cleland JGF, et al
     Global disparities in prescription of guideline-recommended drugs for heart failure with reduced ejection fraction.
     Eur Heart J. 2022 Apr 8. pii: 6564923. doi: 10.1093.
     PubMed     Abstract available
     
     
     
255. KHAN MS, Bakris GL, Packer M, Shahid I, et al
     Kidney function assessment and endpoint ascertainment in clinical trials.
     Eur Heart J. 2022;43:1379-1400.
     PubMed     Abstract available
     
     
     March 2022
256. DMITRIEVA NI, Liu D, Wu CO, Boehm M, et al
     Middle age serum sodium levels in the upper part of normal range and risk of heart failure.
     Eur Heart J. 2022 Mar 29. pii: 6553797. doi: 10.1093.
     PubMed     Abstract available
     
     
     
257. SOLOMON SD, Claggett BL, Miao ZM, Diaz R, et al
     Influence of atrial fibrillation on efficacy and safety of omecamtiv mecarbil in heart failure: the GALACTIC-HF trial.
     Eur Heart J. 2022 Mar 23. pii: 6552734. doi: 10.1093.
     PubMed     Abstract available
     
     
     
258. OKA S, Endo H, Takagi K, Yamagata K, et al
     Mechanical coronary artery stenosis induced by active fixation left ventricular lead: a case of acute complication after cardiac resynchronization therapy device implantation.
     Eur Heart J. 2022;43:1271.
     PubMed    
     
     
     
259. SHAH SJ
     BNP: Biomarker Not Perfect in heart failure with preserved ejection fraction.
     Eur Heart J. 2022 Mar 18. pii: 6550399. doi: 10.1093.
     PubMed    
     
     
     
260. SEQUEIRA V, Maack C
     Cereblon, a novel target in heart failure: but is calcium really everything?
     Eur Heart J. 2022 Mar 16. pii: 6549181. doi: 10.1093.
     PubMed    
     
     
     
261. 
     Clinical presentation, disease course, and outcome of COVID-19 in hospitalized patients with and without pre-existing cardiac disease: a cohort study across 18 countries.
     Eur Heart J. 2022;43:1104-1120.
     PubMed     Abstract available
     
     
     
262. 
     Corrigendum to: Atrial disease and heart failure: the common soil hypothesis proposed by the Heart Failure Association of the European Society of Cardiology.
     Eur Heart J. 2022 Mar 11. pii: 6546740. doi: 10.1093.
     PubMed    
     
     
     
263. ZILE MR, Desai AS, Costanzo MR, Ducharme A, et al
     The GUIDE-HF trial of pulmonary artery pressure monitoring in heart failure: impact of the COVID-19 pandemic.
     Eur Heart J. 2022 Mar 10. pii: 6546019. doi: 10.1093.
     PubMed     Abstract available
     
     
     
264. PRINZEN FW, Auricchio A, Mullens W, Linde C, et al
     Electrical management of heart failure: from pathophysiology to treatment.
     Eur Heart J. 2022 Mar 10. pii: 6546052. doi: 10.1093.
     PubMed     Abstract available
     
     
     
265. VOLPE M, Liuzzo G
     Unloading left heart with a shunt device shows no benefits in heart failure with preserved ejection fraction but supports the importance of phenotyping patients in clinical trials.
     Eur Heart J. 2022 Mar 8. pii: 6544808. doi: 10.1093.
     PubMed    
     
     
     February 2022
266. LIUZZO G, Patrono C
     In vivo generated chimeric antigen receptor T cells reduce fibrosis and restore cardiac function in experimental heart failure.
     Eur Heart J. 2022 Feb 21. pii: 6533290. doi: 10.1093.
     PubMed    
     
     
     
267. RUDOLPH V
     Heart and kidney: towards an integrated approach to secondary mitral regurgitation.
     Eur Heart J. 2022 Feb 18. pii: 6530471. doi: 10.1093.
     PubMed    
     
     
     
268. 
     Corrigendum to: PCSK9 Inhibition in Patients with Heart Failure - Neutral or harmful intervention?
     Eur Heart J. 2022 Feb 15. pii: 6529357. doi: 10.1093.
     PubMed    
     
     
     
269. MUTAGAYWA RK, Chin A, Karaye K, Bonny A, et al
     Unmet needs in the management of arrhythmias among heart failure patients in Africa.
     Eur Heart J. 2022 Feb 15. pii: 6528559. doi: 10.1093.
     PubMed    
     
     
     
270. BRAUNWALD E
     Heart failure: a 70 year Odysseydagger.
     Eur Heart J. 2022 Feb 15. pii: 6528592. doi: 10.1093.
     PubMed    
     
     
     
271. 
     Corrigendum to: Heart failure with preserved ejection fraction in humans and mice: embracing clinical complexity in mouse models.
     Eur Heart J. 2022 Feb 9. pii: 6525416. doi: 10.1093.
     PubMed    
     
     
     
272. VERBRUGGE FH, Omote K, Reddy YNV, Sorimachi H, et al
     Heart failure with preserved ejection fraction in patients with normal natriuretic peptide levels is associated with increased morbidity and mortality.
     Eur Heart J. 2022 Feb 9. pii: 6525335. doi: 10.1093.
     PubMed     Abstract available
     
     
     
273. BEOHAR N, Ailawadi G, Kotinkaduwa LN, Redfors B, et al
     Impact of baseline renal dysfunction on cardiac outcomes and end-stage renal disease in heart failure patients with mitral regurgitation: the COAPT trial.
     Eur Heart J. 2022 Feb 3. pii: 6521532. doi: 10.1093.
     PubMed     Abstract available
     
     
     
274. CREA F
     Treatment of heart failure across the spectrum of left ventricular ejection fraction and an update on cardiac amyloidosis and ischaemic cardiomyopathy.
     Eur Heart J. 2022;43:351-354.
     PubMed    
     
     
     January 2022
275. RUILOPE LM, Ruiz-Hurtado G, Miranda B, Ortiz A, et al
     Use of chronic kidney disease blind spot to prevent cardiorenal outcomes.
     Eur Heart J. 2022;43:257-260.
     PubMed    
     
     
     
276. NIESSNER A, Drexel H
     PCSK9 inhibition in patients with heart failure: neutral or harmful intervention?
     Eur Heart J. 2022 Jan 13. pii: 6507289. doi: 10.1093.
     PubMed    
     
     
     
277. BAUERSACHS J, de Boer RA, Lindenfeld J, Bozkurt B, et al
     The year in cardiovascular medicine 2021: heart failure and cardiomyopathies.
     Eur Heart J. 2022 Jan 3. pii: 6491391. doi: 10.1093.
     PubMed     Abstract available
     
     
     December 2021
278. CREA F
     Sodium-glucose co-transporter inhibitors, iron therapy, and checkpoint inhibitors: new clinical and translational pieces of the heart failure puzzle.
     Eur Heart J. 2021;42:4871-4875.
     PubMed    
     
     
     
279. JOSEPH S, Panniyammakal J, Abdullakutty J, S S, et al
     The Cardiology Society of India-Kerala Acute Heart Failure Registry: poor adherence to guideline-directed medical therapy.
     Eur Heart J. 2021 Dec 21. pii: 6471440. doi: 10.1093.
     PubMed     Abstract available
     
     
     
280. ZANNAD F
     Management of heart failure around the globe. Are we doing enough?
     Eur Heart J. 2021 Dec 21. pii: 6471439. doi: 10.1093.
     PubMed    
     
     
     
281. MARTENS P, Dupont M, Dauw J, Nijst P, et al
     The effect of intravenous ferric carboxymaltose on cardiac reverse remodelling following cardiac resynchronization therapy-the IRON-CRT trial.
     Eur Heart J. 2021;42:4905-4914.
     PubMed     Abstract available
     
     
     
282. WHITE HD, Schwartz GG, Szarek M, Bhatt DL, et al
     Alirocumab after acute coronary syndrome in patients with a history of heart failure.
     Eur Heart J. 2021 Dec 18. pii: 6469637. doi: 10.1093.
     PubMed     Abstract available
     
     
     
283. ADAMO M, Gardner RS, McDonagh TA, Metra M, et al
     The 'Ten Commandments' of the 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure.
     Eur Heart J. 2021 Dec 18. pii: 6469680. doi: 10.1093.
     PubMed    
     
     
     
284. JANKOWSKA EA, Ponikowski P
     Dilemmas on diagnosis and treatment of iron deficiency in patients after an episode of acute heart failure.
     Eur Heart J. 2021 Dec 9. pii: 6458058. doi: 10.1093.
     PubMed    
     
     
     
285. SAWICKI KT, Ardehali H
     Iron therapy on quality of life in acute heart failure: alternative approaches.
     Eur Heart J. 2021 Dec 9. pii: 6458062. doi: 10.1093.
     PubMed    
     
     
     
286. KONDO T, McMurray JJV
     Re-emergence of heart failure with a normal ejection fraction?
     Eur Heart J. 2021 Dec 8. pii: 6455984. doi: 10.1093.
     PubMed    
     
     
     
287. BUTLER J, Packer M, Filippatos G, Ferreira JP, et al
     Effect of empagliflozin in patients with heart failure across the spectrum of left ventricular ejection fraction.
     Eur Heart J. 2021 Dec 8. pii: 6455932. doi: 10.1093.
     PubMed     Abstract available
     
     
     
288. COATS AJS, Heymans S, Farmakis D, Anker SD, et al
     Atrial disease and heart failure: the common soil hypothesis proposed by the Heart Failure Association of the European Society of Cardiology.
     Eur Heart J. 2021 Dec 7. pii: 6454842. doi: 10.1093.
     PubMed    
     
     
     
289. VOLPE M, Patrono C
     The EMPEROR-Preserved study: end of the search for the "Phoenix" or beginning of a new season for trials in heart failure with preserved ejection fraction.
     Eur Heart J. 2021;42:4621-4623.
     PubMed    
     
     
     November 2021
290. ROALFE AK, Lay-Flurrie SL, Ordonez-Mena JM, Goyder CR, et al
     Long term trends in natriuretic peptide testing for heart failure in UK primary care: a cohort study.
     Eur Heart J. 2021 Nov 30. pii: 6437771. doi: 10.1093.
     PubMed     Abstract available
     
     
     
291. CRUMP C, Sundquist J, McLaughlin MA, Dolan SM, et al
     Pre-term delivery and long-term risk of heart failure in women: a national cohort and co-sibling study.
     Eur Heart J. 2021 Nov 24. pii: 6438093. doi: 10.1093.
     PubMed     Abstract available
     
     
     
292. CREA F
     Mechanisms of heart failure with preserved ejection fraction, risk stratification of heart failure with reduced ejection fraction, and new light on resistance to diuretics in acute decompensated heart failure.
     Eur Heart J. 2021;42:4405-4409.
     PubMed    
     
     
     
293. PITT B, Ferreira JP, Zannad F
     Why are mineralocorticoid receptor antagonists the Cinderella in evidence-based treatment of myocardial infarction complicated with heart failure? Lessons from PARADISE-MI.
     Eur Heart J. 2021 Nov 12. pii: 6425576. doi: 10.1093.
     PubMed    
     
     
     
294. ISHIURA J, Nakamori S, Ishida M, Dohi K, et al
     'Targeting the cardiac myocyte and fibrosis' in heart failure.
     Eur Heart J. 2021 Nov 10. pii: 6425003. doi: 10.1093.
     PubMed    
     
     
     
295. LUND LH, Hage C, Savarese G
     Implementation science and potential for screening in heart failure.
     Eur Heart J. 2021 Nov 9. pii: 6424186. doi: 10.1093.
     PubMed    
     
     
     
296. EGIDY ASSENZA G, Dimopoulos K, Budts W, Donti A, et al
     Management of acute cardiovascular complications in pregnancy.
     Eur Heart J. 2021;42:4224-4240.
     PubMed     Abstract available
     
     
     October 2021
297. BUTLER J, Anker SD, Filippatos G, Usman MS, et al
     Sodium glucose co-transporter inhibitors and heart failure outcomes across different patient populations.
     Eur Heart J. 2021 Oct 30. pii: 6414464. doi: 10.1093.
     PubMed    
     
     
     
298. SEFEROVIC PM, Piepoli M, Polovina M, Milinkovic I, et al
     ESC/HFA Quality of Care Centres: the ultimate frontier in unifying heart failure management.
     Eur Heart J. 2021 Oct 28. pii: 6413707. doi: 10.1093.
     PubMed    
     
     
     
299. MCDONAGH TA, Metra M, Adamo M, Gardner RS, et al
     Corrigendum to: 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: Developed by the Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC) With the
     Eur Heart J. 2021 Oct 14. pii: 6397185. doi: 10.1093.
     PubMed    
     
     
     
300. BRAUNWALD E
     Heart failure with preserved ejection fraction: a stepchild no more!
     Eur Heart J. 2021;42:3900-3901.
     PubMed    
     
     
     
301. SATTAR N, Anker SD, Butler J, Verma S, et al
     Obesity, heart failure, and SGLT2 inhibition: DECLARE-TIMI 58 provides insights.
     Eur Heart J. 2021 Oct 7. pii: 6383062. doi: 10.1093.
     PubMed    
     
     
     
302. LINDE C
     Pace and ablate better than drugs in patients with heart failure and atrial fibrillation: lessons from the APAF-CRT mortality trial.
     Eur Heart J. 2021 Oct 6. pii: 6382271. doi: 10.1093.
     PubMed    
     
     
     September 2021
303. CREA F
     The ESC Guidelines on heart failure, sacubitril-valsartan in resistant hypertension, and new therapeutic targets in myocardial hypertrophy.
     Eur Heart J. 2021;42:3581-3585.
     PubMed    
     
     
     
304. ZHAO Y, Ling S, Li J, Zhong G, et al
     3' untranslated region of Ckip-1 inhibits cardiac hypertrophy independently of its cognate protein.
     Eur Heart J. 2021;42:3786-3799.
     PubMed     Abstract available
     
     
     
305. CHEN QQ, Ma G, Liu JF, Cai YY, et al
     Neuraminidase 1 is a driver of experimental cardiac hypertrophy.
     Eur Heart J. 2021;42:3770-3782.
     PubMed     Abstract available
     
     
     
306. WUSSLER D, Mueller C
     Biomarker-driven prognostic model for risk prediction in heart failure: ready for Prime time?
     Eur Heart J. 2021 Sep 17. pii: 6371853. doi: 10.1093.
     PubMed    
     
     
     
307. SINHA A, Rahman H, Webb A, Shah AM, et al
     Untangling the pathophysiologic link between coronary microvascular dysfunction and heart failure with preserved ejection fraction.
     Eur Heart J. 2021 Sep 16. pii: 6371296. doi: 10.1093.
     PubMed     Abstract available
     
     
     
308. MARTENS P, Tang WHW, Mullens W
     Renal sodium avidity, the prevailing renal target in heart failure.
     Eur Heart J. 2021 Sep 16. pii: 6371295. doi: 10.1093.
     PubMed    
     
     
     
309. COX ZL, Rao VS, Ivey-Miranda JB, Moreno-Villagomez J, et al
     Compensatory post-diuretic renal sodium reabsorption is not a dominant mechanism of diuretic resistance in acute heart failure.
     Eur Heart J. 2021 Sep 16. pii: 6371304. doi: 10.1093.
     PubMed     Abstract available
     
     
     
310. 
     Erratum to: CDR132L improves systolic and diastolic function in a large animal model of chronic heart failure.
     Eur Heart J. 2021 Sep 14. pii: 6370281. doi: 10.1093.
     PubMed    
     
     
     
311. JANKOWSKA EA, Ponikowski P
     Intravenous iron supplementation: novel anti-remodelling therapy for patients with heart failure?
     Eur Heart J. 2021 Sep 14. pii: 6370026. doi: 10.1093.
     PubMed    
     
     
     
312. CREA F
     The ESC Guidelines on cardiac pacing and resynchronization, and the many facets of atrial fibrillation.
     Eur Heart J. 2021;42:3411-3414.
     PubMed    
     
     
     
313. GLIKSON M, Nielsen JC, Kronborg MB, Michowitz Y, et al
     2021 ESC Guidelines on cardiac pacing and cardiac resynchronization therapy.
     Eur Heart J. 2021;42:3427-3520.
     PubMed    
     
     
     
314. BAYES-GENIS A, Diez J
     Transition to heart failure in hypertension: going to the heart of the matter.
     Eur Heart J. 2021 Sep 13. pii: 6369562. doi: 10.1093.
     PubMed    
     
     
     
315. LEWIS EF
     A fourth pillar for all in the treatment of heart failure.
     Eur Heart J. 2021 Sep 13. pii: 6369563. doi: 10.1093.
     PubMed    
     
     
     
316. KAHN M, Grayson AD, Chaggar PS, Ng Kam Chuen MJ, et al
     Primary care heart failure service identifies a missed cohort of heart failure patients with reduced ejection fraction.
     Eur Heart J. 2021 Sep 11. pii: 6368904. doi: 10.1093.
     PubMed     Abstract available
     
     
     
317. BROWN JM, Zhou W, Weber B, Divakaran S, et al
     Low coronary flow relative to myocardial mass predicts heart failure in symptomatic hypertensive patients with no obstructive coronary artery disease.
     Eur Heart J. 2021 Sep 7. pii: 6365821. doi: 10.1093.
     PubMed     Abstract available
     
     
     August 2021
318. YILMAZ MB
     Does early angiography pave the way for improved outcomes in patients with acute heart failure?
     Eur Heart J. 2021 Aug 31. pii: 6360027. doi: 10.1093.
     PubMed    
     
     
     
319. MCDONAGH TA, Metra M, Adamo M, Gardner RS, et al
     2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure.
     Eur Heart J. 2021 Aug 27. pii: 6358045. doi: 10.1093.
     PubMed    
     
     
     
320. LIGHT PE
     Decoding the effects of SGLT2 inhibitors on cardiac arrhythmias in heart failure.
     Eur Heart J. 2021 Aug 27. pii: 6358226. doi: 10.1093.
     PubMed    
     
     
     
321. CURTAIN JP, Docherty KF, Jhund PS, Petrie MC, et al
     Effect of dapagliflozin on ventricular arrhythmias, resuscitated cardiac arrest, or sudden death in DAPA-HF.
     Eur Heart J. 2021 Aug 27. pii: 6358075. doi: 10.1093.
     PubMed     Abstract available
     
     
     
322. POCOCK SJ, Ferreira JP, Gregson J, Anker SD, et al
     Novel biomarker-driven prognostic models to predict morbidity and mortality in chronic heart failure: the EMPEROR-Reduced trial.
     Eur Heart J. 2021 Aug 23. pii: 6356321. doi: 10.1093.
     PubMed     Abstract available
     
     
     
323. CREA F
     The complex relationship among heart failure, cancer, and lipid lowering, and an update on cardiomyopathies.
     Eur Heart J. 2021;42:3029-3032.
     PubMed    
     
     
     
324. BERGER M, Solelhac G, Roche F, Heinzer R, et al
     Insomnia, a new modifiable risk factor for heart failure?
     Eur Heart J. 2021 Aug 21. pii: 6355986. doi: 10.1093.
     PubMed    
     
     
     
325. WITHAAR C, Lam CSP, Schiattarella GG, de Boer RA, et al
     Heart failure with preserved ejection fraction in humans and mice: embracing clinical complexity in mouse models.
     Eur Heart J. 2021 Aug 20. pii: 6355308. doi: 10.1093.
     PubMed     Abstract available
     
     
     
326. KEMPF T
     Iron supplementation in acute heart failure: energize your life.
     Eur Heart J. 2021;42:3021-3022.
     PubMed    
     
     
     
327. VOLPE M, Gallo G
     Sacubitril/valsartan for heart failure with preserved ejection fraction and resistant hypertension: one shot for a double strike?
     Eur Heart J. 2021 Aug 15. pii: 6352588. doi: 10.1093.
     PubMed    
     
     
     
328. MAHMOOD A, Ray M, Dobalian A, Ward KD, et al
     Insomnia symptoms and incident heart failure: a population-based cohort study.
     Eur Heart J. 2021 Aug 15. pii: 6352589. doi: 10.1093.
     PubMed     Abstract available
     
     
     
329. WAGNER JUG, Dimmeler S
     The endothelial niche in heart failure: from development to regeneration.
     Eur Heart J. 2021 Aug 15. pii: 6352586. doi: 10.1093.
     PubMed    
     
     
     
330. JACKSON AM, Jhund PS, Anand IS, Dungen HD, et al
     Sacubitril-valsartan as a treatment for apparent resistant hypertension in patients with heart failure and preserved ejection fraction.
     Eur Heart J. 2021 Aug 15. pii: 6352587. doi: 10.1093.
     PubMed     Abstract available
     
     
     
331. DIVAKARAN S, Nohria A
     Decoding the link between heart failure and incident cancer.
     Eur Heart J. 2021 Aug 14. pii: 6352225. doi: 10.1093.
     PubMed    
     
     
     
332. WANG N, Sun Y, Zhang H, Wang B, et al
     Long-term night shift work is associated with the risk of atrial fibrillation and coronary heart disease.
     Eur Heart J. 2021 Aug 10. pii: 6347324. doi: 10.1093.
     PubMed     Abstract available
     
     
     
333. NICHOLLS M
     New perspectives on heart failure.
     Eur Heart J. 2021 Aug 6. pii: 6343116. doi: 10.1093.
     PubMed    
     
     
     July 2021
334. KOSYAKOVSKY LB, Austin PC, Ross HJ, Wang X, et al
     Early invasive coronary angiography and acute ischaemic heart failure outcomes.
     Eur Heart J. 2021 Jul 30. pii: 6331345. doi: 10.1093.
     PubMed     Abstract available
     
     
     
335. TUAL-CHALOT S, Stellos K
     Drug repurposing to prevent pressure overload-induced cardiac hypertrophy and heart failure.
     Eur Heart J. 2021 Jul 13. pii: 6319852. doi: 10.1093.
     PubMed    
     
     
     
336. DA DALT L, Castiglioni L, Baragetti A, Audano M, et al
     PCSK9 deficiency rewires heart metabolism and drives heart failure with preserved ejection fraction.
     Eur Heart J. 2021 Jul 12. pii: 6319627. doi: 10.1093.
     PubMed     Abstract available
     
     
     
337. 
     European Heart Journal Team Heart Failure.
     Eur Heart J. 2021 Jul 5. pii: 6314555. doi: 10.1093.
     PubMed    
     
     
     
338. ONO M, Garg S, Onuma Y, Serruys PW, et al
     Coronary artery bypass grafting versus percutaneous coronary intervention in ischaemic heart failure. Can reliable treatment decisions in high-risk patients be based on non-randomized data?
     Eur Heart J. 2021 Jul 1. pii: 6311994. doi: 10.1093.
     PubMed    
     
     
     June 2021
339. LAM CSP, Ferreira JP, Pfarr E, Sim D, et al
     Regional and ethnic influences on the response to empagliflozin in patients with heart failure and a reduced ejection fraction: the EMPEROR-Reduced trial.
     Eur Heart J. 2021 Jun 29. pii: 6310468. doi: 10.1093.
     PubMed     Abstract available
     
     
     
340. REN QW, Yu SY, Teng TK, Li X, et al
     Statin associated lower cancer risk and related mortality in patients with heart failure.
     Eur Heart J. 2021 Jun 22. pii: 6307232. doi: 10.1093.
     PubMed     Abstract available
     
     
     
341. CREA F
     The Universal Definition of Heart Failure, risk prediction in cardiogenic shock, artificial intelligence in cardiac allograft rejection, and the genetics of dilated cardiomyopathy.
     Eur Heart J. 2021;42:2317-2320.
     PubMed    
     
     
     
342. NICHOLLS M
     Recognition for heart failure breakthrough.
     Eur Heart J. 2021 Jun 11. pii: 6296965. doi: 10.1093.
     PubMed    
     
     
     
343. JANKOWSKA EA, Kirwan BA, Kosiborod M, Butler J, et al
     The effect of intravenous ferric carboxymaltose on health-related quality of life in iron-deficient patients with acute heart failure: the results of the AFFIRM-AHF study.
     Eur Heart J. 2021 Jun 3. pii: 6291468. doi: 10.1093.
     PubMed     Abstract available
     
     
     
344. ZANNAD F, Cotter G, Alonso Garcia A, George S, et al
     What can heart failure trialists learn from oncology trialists?
     Eur Heart J. 2021 Jun 2. pii: 6291019. doi: 10.1093.
     PubMed     Abstract available
     
     
     May 2021
345. VOLZ S, Redfors B, Angeras O, Ioanes D, et al
     Long-term mortality in patients with ischaemic heart failure revascularized with coronary artery bypass grafting or percutaneous coronary intervention: insights from the Swedish Coronary Angiography and Angioplasty Registry (SCAAR).
     Eur Heart J. 2021 May 23. pii: 6282431. doi: 10.1093.
     PubMed     Abstract available
     
     
     
346. MARSTON NA, Han L, Olivotto I, Day SM, et al
     Clinical characteristics and outcomes in childhood-onset hypertrophic cardiomyopathy.
     Eur Heart J. 2021;42:1988-1996.
     PubMed     Abstract available
     
     
     
347. PORCHER R, Desguerre I, Amthor H, Chabrol B, et al
     Association between prophylactic angiotensin-converting enzyme inhibitors and overall survival in Duchenne muscular dystrophy-analysis of registry data.
     Eur Heart J. 2021;42:1976-1984.
     PubMed     Abstract available
     
     
     
348. HAMDANI N, Costantino S, Mugge A, Lebeche D, et al
     Leveraging clinical epigenetics in heart failure with preserved ejection fraction: a call for individualized therapies.
     Eur Heart J. 2021;42:1940-1958.
     PubMed     Abstract available
     
     
     
349. NICHOLLS M
     Telemedicine for chronic heart failure patients.
     Eur Heart J. 2021 May 13. pii: 6274945. doi: 10.1093.
     PubMed    
     
     
     
350. HAMDANI N, Costantino S, Mugge A, Lebeche D, et al
     Leveraging clinical epigenetics in heart failure with preserved ejection fraction: a call for individualized therapies.
     Eur Heart J. 2021 May 5. pii: 6264879. doi: 10.1093.
     PubMed     Abstract available
     
     
     April 2021
351. 
     Corrigendum to: Genome-wide association analysis in dilated cardiomyopathy reveals two new players in systolic heart failure on chromosomes 3p25.1 and 22q11.23.
     Eur Heart J. 2021 Apr 24. pii: 6248970. doi: 10.1093.
     PubMed    
     
     
     
352. CREA F
     Emerging causes and risk factors of heart failure: amyloidosis, myocarditis, immune checkpoint inhibitors, air pollution, and visceral adipose tissue.
     Eur Heart J. 2021;42:1533-1537.
     PubMed    
     
     
     
353. RAJAGOPALAN S, Brook RD, Al-Kindi S
     Air pollution and flooding in the lungs: modern insights into ancient problems.
     Eur Heart J. 2021;42:1592-1594.
     PubMed    
     
     
     
354. WITHAAR C, Meems LMG, de Boer RA
     Fighting HFpEF in women: taking aim at belly fat.
     Eur Heart J. 2021;42:1606-1608.
     PubMed    
     
     
     
355. FULLENKAMP DE, Puckelwartz MJ, McNally EM
     Genome-wide association for heart failure: from discovery to clinical use.
     Eur Heart J. 2021 Apr 14. pii: 6225796. doi: 10.1093.
     PubMed    
     
     
     
356. 
     Erratum to: Conducting Clinical Trials in Heart Failure During (and After) the COVID-19 Pandemic: An Expert Consensus Position Paper from the Heart Failure Association (HFA) of the European Society of Cardiology (ESC).
     Eur Heart J. 2021 Apr 7. pii: 6214477. doi: 10.1093.
     PubMed    
     
     
     
357. BAUERSACHS J
     The struggle towards a Universal Definition of Heart Failure-how to proceed?
     Eur Heart J. 2021 Apr 1. pii: 6206998. doi: 10.1093.
     PubMed    
     
     
     March 2021
358. CREA F
     Challenges in heart failure: quality of life, chronic kidney disease, and secondary mitral regurgitation.
     Eur Heart J. 2021;42:1185-1189.
     PubMed    
     
     
     
359. SPERTUS JA
     Quality of life in EMPEROR-Reduced: emphasizing what is important to patients while identifying strategies to support more patient-centred care.
     Eur Heart J. 2021;42:1213-1215.
     PubMed    
     
     
     
360. FUKUOKA R, Kawamura A, Kohsaka S
     Prediction of sudden arrhythmic death in patients with heart failure: towards validation in a worldwide broader range of patients.
     Eur Heart J. 2021 Mar 18. pii: 6177055. doi: 10.1093.
     PubMed    
     
     
     
361. COATS AJS, Anker SD, Baumbach A, Alfieri O, et al
     The management of secondary mitral regurgitation in patients with heart failure: a joint position statement from the Heart Failure Association (HFA), European Association of Cardiovascular Imaging (EACVI), European Heart Rhythm Association (EHRA), and
     Eur Heart J. 2021 Mar 18. pii: 6174642. doi: 10.1093.
     PubMed     Abstract available
     
     
     
362. YOUNIS A, Goldenberg I
     Extending the MADIT-ICD benefit score to heterogenous heart failure populations.
     Eur Heart J. 2021 Mar 18. pii: 6177051. doi: 10.1093.
     PubMed    
     
     
     
363. VOLPE M, Patrono C
     The value of sotagliflozin in patients with diabetes and heart failure detracted by an unexpected ending.
     Eur Heart J. 2021 Mar 10. pii: 6168016. doi: 10.1093.
     PubMed    
     
     
     
364. GARNIER S, Harakalova M, Weiss S, Mokry M, et al
     Genome-wide association analysis in dilated cardiomyopathy reveals two new players in systolic heart failure on chromosomes 3p25.1 and 22q11.23.
     Eur Heart J. 2021 Mar 3. pii: 6157424. doi: 10.1093.
     PubMed     Abstract available
     
     
     
365. VAN DIEPEN S, Armstrong PW
     Learning whether to subtract beta-blockers: it's about time.
     Eur Heart J. 2021;42:915-918.
     PubMed     Abstract available
     
     
     February 2021
366. VOLPE M, Patrono C
     Iron heart.
     Eur Heart J. 2021;42:809-810.
     PubMed    
     
     
     
367. DIDERIKSEN JR, Christiansen MK, Johansen JB, Nielsen JC, et al
     Long-term outcomes in young patients with atrioventricular block of unknown aetiology.
     Eur Heart J. 2021 Feb 18. pii: 6143533. doi: 10.1093.
     PubMed     Abstract available
     
     
     
368. VILLRINGER A, Laufs U
     Heart failure, cognition, and brain damage.
     Eur Heart J. 2021 Feb 16. pii: 6139887. doi: 10.1093.
     PubMed    
     
     
     
369. HALLIDAY BP, Senior R, Pennell DJ
     Assessing left ventricular systolic function: from ejection fraction to strain analysis.
     Eur Heart J. 2021;42:789-797.
     PubMed     Abstract available
     
     
     
370. CREA F
     New guidelines on adult congenital heart disease, the fantastic four in the treatment of heart failure, and also what happened in the last year in heart failure and valvular heart disease.
     Eur Heart J. 2021;42:551-554.
     PubMed    
     
     
     
371. 
     Corrigendum to: The Year in Cardiovascular Medicine: Heart Failure and Cardiomyopathies. The Year in Cardiovascular Medicine 2020.
     Eur Heart J. 2021 Feb 11. pii: 6132731. doi: 10.1093.
     PubMed    
     
     
     
372. PETRIE MC, Lee MM, Lang NN
     EMPEROR-REDUCED reigns while EMPERIAL whimpers.
     Eur Heart J. 2021;42:711-714.
     PubMed    
     
     
     
373. WANG M, Zhou T, Song Y, Li X, et al
     Joint exposure to various ambient air pollutants and incident heart failure: a prospective analysis in UK Biobank.
     Eur Heart J. 2021 Feb 2. pii: 6126215. doi: 10.1093/eurheartj/ehaa1031.
     PubMed     Abstract available
     
     
     January 2021
374. LOCH A, Koh PS, Manokaran P
     Giant hepatic cyst masquerading as right heart failure.
     Eur Heart J. 2021 Jan 30. pii: 6124029. doi: 10.1093.
     PubMed    
     
     
     
375. FREY A, Homola GA, Henneges C, Muhlbauer L, et al
     Temporal changes in total and hippocampal brain volume and cognitive function in patients with chronic heart failure-the COGNITION.MATTERS-HF cohort study.
     Eur Heart J. 2021 Jan 26. pii: 6120261. doi: 10.1093.
     PubMed     Abstract available
     
     
     
376. 
     Corrigendum to: Does hypoperfusion outperform blood pressure as a better predictor in the risk stratification of acute heart failure?
     Eur Heart J. 2021;42:319.
     PubMed    
     
     
     
377. MASSIMO V, Carlo P
     Truly galactic?
     Eur Heart J. 2021;42:296-297.
     PubMed    
     
     
     
378. EVANS MA, Sano S, Walsh K
     Clonal haematopoiesis and cardiovascular disease: how low can you go?
     Eur Heart J. 2021;42:266-268.
     PubMed    
     
     
     
379. SMISETH OA, Aalen JM, Skulstad H
     Heart failure and systolic function: time to leave diagnostics based on ejection fraction?
     Eur Heart J. 2021 Jan 17. pii: 6075085. doi: 10.1093.
     PubMed    
     
     
     
380. BAUERSACHS J
     Heart failure drug treatment: the fantastic four.
     Eur Heart J. 2021 Jan 14. pii: 6099035. doi: 10.1093/eurheartj/ehaa1012.
     PubMed    
     
     
     
381. CSENGERI D, Sprunker NA, Di Castelnuovo A, Niiranen T, et al
     Alcohol consumption, cardiac biomarkers, and risk of atrial fibrillation and adverse outcomes.
     Eur Heart J. 2021 Jan 13. pii: 6090248. doi: 10.1093.
     PubMed     Abstract available
     
     
     
382. HOLT A, Blanche P, Zareini B, Rajan D, et al
     Effect of long-term beta-blocker treatment following myocardial infarction among stable, optimally treated patients without heart failure in the reperfusion era: a Danish, nationwide cohort study.
     Eur Heart J. 2021 Jan 11. pii: 6082772. doi: 10.1093/eurheartj/ehaa1058.
     PubMed     Abstract available
     
     
     
383. PACKER M, Anker SD, Butler J, Filippatos G, et al
     Influence of neprilysin inhibition on the efficacy and safety of empagliflozin in patients with chronic heart failure and a reduced ejection fraction: the EMPEROR-Reduced trial.
     Eur Heart J. 2021 Jan 11. pii: 6081935. doi: 10.1093.
     PubMed     Abstract available
     
     
     
384. BUTLER J, Anker SD, Filippatos G, Khan MS, et al
     Empagliflozin and health-related quality of life outcomes in patients with heart failure with reduced ejection fraction: the EMPEROR-Reduced trial.
     Eur Heart J. 2021 Jan 9. pii: 6072066. doi: 10.1093/eurheartj/ehaa1007.
     PubMed     Abstract available
     
     
     
385. CREA F
     Machine learning-guided phenotyping of dilated cardiomyopathy and treatment of heart failure by antisense oligonucleotides: the future has begun.
     Eur Heart J. 2021;42:139-142.
     PubMed    
     
     
     
386. DEVAUX Y, Badimon L
     CDR132L: another brick in the wall towards the use of miRNAs to treat cardiovascular disease.
     Eur Heart J. 2021;42:202-204.
     PubMed    
     
     
     
387. AGARWAL R, Kolkhof P, Bakris G, Bauersachs J, et al
     Steroidal and non-steroidal mineralocorticoid receptor antagonists in cardiorenal medicine.
     Eur Heart J. 2021;42:152-161.
     PubMed     Abstract available
     
     
     
388. FURHOLZ M, Gisler F, Hunziker L, Huber AT, et al
     Posture dependent dynamic external outflow graft compression in HeartMate 3TM left ventricular assist device.
     Eur Heart J. 2021;42:205.
     PubMed    
     
     
     
389. BUENO H, Moura B, Lancellotti P, Bauersachs J, et al
     The year in cardiovascular medicine 2020: heart failure and cardiomyopathies.
     Eur Heart J. 2021 Jan 3. pii: 6060054. doi: 10.1093/eurheartj/ehaa1061.
     PubMed    
     
     
     December 2020
390. 
     Corrigendum to: How to Diagnose Heart Failure with Preserved Ejection Fraction - The HFA-PEFF-SCORE An updated Consensus Statement of the Heart Failure Association (HFA) of the European Society of Cardiology (ESC).
     Eur Heart J. 2020 Dec 29. pii: 6055039. doi: 10.1093/eurheartj/ehaa1016.
     PubMed    
     
     
     
391. ABRAHAM WT, Lindenfeld J, Ponikowski P, Agostoni P, et al
     Effect of empagliflozin on exercise ability and symptoms in heart failure patients with reduced and preserved ejection fraction, with and without type 2 diabetes.
     Eur Heart J. 2020 Dec 22. pii: 6044442. doi: 10.1093.
     PubMed     Abstract available
     
     
     
392. BAKER AH, Giacca M
     Antagonism of miRNA in heart failure: first evidence in human.
     Eur Heart J. 2020 Dec 18. pii: 6041762. doi: 10.1093.
     PubMed    
     
     
     
393. ROY R, Koch WJ
     Adding another GRK to the fire of heart failure.
     Eur Heart J. 2020 Dec 7. pii: 6025474. doi: 10.1093.
     PubMed    
     
     
     November 2020
394. PITT B, Byrd JB
     Detection of patients at risk of developing heart failure responsive to mineralocorticoid receptor antagonists (MRAs): new insights and opportunities.
     Eur Heart J. 2020 Nov 30. pii: 6012925. doi: 10.1093.
     PubMed    
     
     
     
395. ASSMUS B, Cremer S, Kirschbaum K, Culmann D, et al
     Clonal haematopoiesis in chronic ischaemic heart failure: prognostic role of clone size for DNMT3A- and TET2-driver gene mutations.
     Eur Heart J. 2020 Nov 26. pii: 6006386. doi: 10.1093.
     PubMed     Abstract available
     
     
     
396. SORIMACHI H, Obokata M, Takahashi N, Reddy YNV, et al
     Pathophysiologic importance of visceral adipose tissue in women with heart failure and preserved ejection fraction.
     Eur Heart J. 2020 Nov 23. pii: 5998959. doi: 10.1093.
     PubMed     Abstract available
     
     
     
397. BOHM M, Mahfoud F
     J-curve revisited.
     Eur Heart J. 2020;41:4283.
     PubMed    
     
     
     
398. LIEW CH, McEvoy JW
     The diastolic blood pressure J-curve remains an observational research phenomenon that has not yet been proven as causal and should not be used to make invasive treatment decisions.
     Eur Heart J. 2020;41:4284-4285.
     PubMed    
     
     
     
399. FEDCHENKO M, Mandalenakis Z, Giang KW, Rosengren A, et al
     Long-term outcomes after myocardial infarction in middle-aged and older patients with congenital heart disease-a nationwide study.
     Eur Heart J. 2020 Nov 21. pii: 5997447. doi: 10.1093.
     PubMed     Abstract available
     
     
     
400. CLELAND JGF, Ferreira JP, Mariottoni B, Pellicori P, et al
     The effect of spironolactone on cardiovascular function and markers of fibrosis in people at increased risk of developing heart failure: the heart 'OMics' in AGEing (HOMAGE) randomized clinical trial.
     Eur Heart J. 2020 Nov 20. pii: 5993916. doi: 10.1093.
     PubMed     Abstract available
     
     
     
401. ALFONSO F
     Heart Failure 2019.
     Eur Heart J. 2020 Nov 17. pii: 5986679. doi: 10.1093.
     PubMed    
     
     
     
402. TAUBEL J, Hauke W, Rump S, Viereck J, et al
     Novel antisense therapy targeting microRNA-132 in patients with heart failure: results of a first-in-human Phase 1b randomized, double-blind, placebo-controlled study.
     Eur Heart J. 2020 Nov 11. pii: 5974817. doi: 10.1093.
     PubMed     Abstract available
     
     
     October 2020
403. 
     Corrigendum to: Treatment of heart failure with reduced ejection fraction: the dawn of sodium-glucose cotransporter-2 inhibitors.
     Eur Heart J. 2020 Oct 22. pii: 5935857. doi: 10.1093.
     PubMed    
     
     
     
404. BATKAI S, Genschel C, Viereck J, Rump S, et al
     CDR132L improves systolic and diastolic function in a large animal model of chronic heart failure.
     Eur Heart J. 2020 Oct 22. pii: 5934677. doi: 10.1093.
     PubMed     Abstract available
     
     
     
405. CREA F
     The multiple causes and treatments of heart failure: focus on genetic and molecular mechanisms and non-pharmacological interventions.
     Eur Heart J. 2020;41:3769-3773.
     PubMed    
     
     
     
406. BONNET M, Champagnac A, Lantelme P, Harbaoui B, et al
     Endomyocardial biopsy findings in Kawasaki-like disease associated with SARS-CoV-2.
     Eur Heart J. 2020;41:3863-3864.
     PubMed    
     
     
     
407. PETTIT SJ
     HeartMate 3: real-world performance matches pivotal trial.
     Eur Heart J. 2020;41:3810-3812.
     PubMed    
     
     
     
408. LIUZZO G, Patrono C
     EMPEROR-Reduced supports the use of SGLT2 inhibitors for the treatment of patients with heart failure and reduced ejection fraction: Comment on the EMPEROR-Reduced trial.
     Eur Heart J. 2020 Oct 7. pii: 5918827. doi: 10.1093.
     PubMed    
     
     
     September 2020
409. CREA F
     Treatment of heart failure: the dawn of the era of sodium-glucose co-transporter-2 inhibitors.
     Eur Heart J. 2020;41:3379-3383.
     PubMed    
     
     
     July 2020
410. HARARI R, Bangalore S
     Beta-blockers after acute myocardial infarction: an old drug in urgent need of new evidence!
     Eur Heart J. 2020 Jul 30. pii: 5879119. doi: 10.1093.
     PubMed    
     
     
     
411. LUSCHER TF
     How to slice the pie: heart failure subgroups and their clinical meaning.
     Eur Heart J. 2020;41:2339-2343.
     PubMed    
     
     
     
412. SCHMIDT IM, Verma A, Waikar SS
     Circulating plasma angiotensin-converting enzyme 2 concentrations in patients with kidney disease.
     Eur Heart J. 2020;41:3097-3098.
     PubMed    
     
     
     May 2020
413. LUSCHER TF
     Cardio-oncology and the future of heart failure.
     Eur Heart J. 2020;41:1709-1712.
     PubMed    
     
     
     
414. MILLER VM
     Universality of sex differences in cardiovascular outcomes: where do we go from here?
     Eur Heart J. 2020;41:1697-1699.
     PubMed    
     
     
     April 2020
415. LUSCHER TF
     Sex and gender and cardiovascular medicine: impact in diabetes, acute coronary syndromes, and heart failure.
     Eur Heart J. 2020;41:1311-1314.
     PubMed    
     
     
     March 2020
416. GOLDENBERG I, Huang DT, Nielsen JC
     The role of implantable cardioverter-defibrillators in asymptomatic patients with left ventricular dysfunction.
     Eur Heart J. 2020 Mar 25. pii: 5811613. doi: 10.1093.
     PubMed    
     
     
     
417. LUSCHER TF
     Ejection fraction to classify heart failure: are we using the right thing?
     Eur Heart J. 2020;41:1219-1222.
     PubMed    
     
     
     
418. MESSERLI FH, Bangalore S, Messerli AW, Raber L, et al
     The muddy waters of the J-curve and coronary revascularization.
     Eur Heart J. 2020 Mar 2. pii: 5771269. doi: 10.1093.
     PubMed    
     
     
     December 2019
419. MALMBORG M, Schmiegelow MDS, Norgaard CH, Munch A, et al
     Does type 2 diabetes confer higher relative rates of cardiovascular events in women compared with men?
     Eur Heart J. 2019 Dec 20. pii: 5682397. doi: 10.1093.
     PubMed     Abstract available
     
     
     November 2019
420. GOLDENBERG I, Huang DT, Nielsen JC
     The role of implantable cardioverter-defibrillators and sudden cardiac death prevention: indications, device selection, and outcome.
     Eur Heart J. 2019 Nov 12. pii: 5622905. doi: 10.1093.
     PubMed     Abstract available
     
     
     September 2019
421. WIJTVLIET EPJP, Tieleman RG, van Gelder IC, Pluymaekers NAHA, et al
     Nurse-led vs. usual-care for atrial fibrillation.
     Eur Heart J. 2019 Sep 23. pii: 5572602. doi: 10.1093.
     PubMed     Abstract available
     
     
     June 2019
422. GENTILLE LORENTE DI
     Coconut atrium: a rare entity to cause pulmonary hypertension.
     Eur Heart J. 2019 Jun 4. pii: 5510776. doi: 10.1093.
     PubMed    
     
     

Thank you for your interest in scientific medicine.

AMEDEO Chronic Heart Failure is free of charge.